
Title: A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of 
TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic 
Gastroparesis
Study ID: [REMOVED]
Protocol Approve Date: 19 December 2018
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1.0 TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
A Dose -Ranging, Randomized, Parallel, Placebo -Controlled Study to Assess the Effect of 
TAK -954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic 
Gastroparesis
Effect of TAK -954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic 
Gastroparesis Patients
Sponsor: Takeda Development Center Americas, Inc. 
Study Number: TAK -954-2003
IND Number: 114408 EudraCT Number: Not Applicable
Compound: TAK -
954
Date: 19 December 2018 Version/Amendment 
Number:05
Amendment History: 
Date Amendment Number Region
28 July  2017 Initial version Global
06 November 2017 01 Global
28 February 2018 02 Global
26 April 2018 03 Global
11 September 2018 04 Global
19 December 2018 05 Global
Property or non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 2of 86
Protocol Incorporating Amendment No. 05 19 December 2018
1.0 ADMINISTRATIVE INFORMATION
1.1 Contacts
A separate contact informat ion list will be provided to each site.
Takeda Development Center Americas, Inc. (TDC) sponsored invest igators per individual 
country  requi rements will be provided wit h emergency medical contact information cards to be 
carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role United States Contact
Serious adverse event and pregnancy reporting Pharmacovigilance, Takeda Development Center Americas, 
Inc. 
Medical Monitor
(medical advice on protocol and study drug)Medical Director, Clinical Science
Responsible Medical Officer 
(carries overall responsibility for the conduct of the 
study)Medical Director, Clinical Science
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 3of 86
Protocol Incorporating Amendment No. 05 19 December 2018
1.2 Approval 
REPRESENTATIVES OF TAKEDA
This study  will be conducted wi th the highest respect for the individual participants in 
accordance with the requirements of this study  protocol  and also in accordance wit h the 
following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation E6 Good Clinical Pract ice: Conso lidated Guideline.
All applicable laws and regulat ions, including , without limi tation, data privacy laws, clinical trial 
disclosure l aws, and regul ations.
SIGNATURES
The signature of the responsible Takeda medical officer can be found on the signature page.
Electronic Signatures are provided on the last page of this doc ument.
Property of Takeda: For no ubject to the applicable Terms of Use
PPD
TAK -954
Study No. TAK -954-2003 Page 4of 86
Protocol Incorporating Amendment No. 05 19 December 2018
INVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, 
package insert and any other product informat ion provi ded by the sponsor. I agree to conduct this 
study  in accordance with the requirements of this protocol and also to protect the rights, safet y, 
privacy , and well -being o f study  subjects in accordance with the following:
The ethi cal principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the study site agreement.
Responsibilit ies o f the Invest igator ( Appendix Aand Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Dof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 5of 86
Protocol Incorporating Amendment No. 05 19 December 2018
1.3 Protocol Amendment 05 Summary of Changes
Rationale for Amendment 05
This document describes the changes in reference to the protocol incorporating Amendment 05. 
The primary  reason for thi s amendment is the eliminat ion of 1 dosing arm based on the results of 
the interim analysis. The opportunit y was taken to make addit ional chan ges.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only. 
For specific descript ions of text changes and where the changes are located, see Appendix F.
Changes in Amendment 05
1.Revised number of subjects based on the findings of the interim analysis.
2.Decreased the number of act ive treatment arms.
3.Revised the ty pe of vi tal sign procedures collected and clarified the timing in relation to 
pharmacokinet ic (PK) blood draws.
4.Eliminat ion of opti onal PK samples.
5. Revised the timing of vital sign measurements. 
6.Eliminated instruction of the timing o f PK sam pling and electrocardi ogram procedures.
7.Revised informat ion related to interim analysis.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 6of 86
Protocol Incorporating Amendment No. 05 19 December 2018
TABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ........................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Ame ndment 05 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 11
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 15
3.1 Study -Related Responsibilit ies................................................................................. 15
3.2 List of Abbreviat ions............................................................................................... 16
3.3 Corporate Identificat ion........................................................................................... 17
4.0 INTRODUCTION ......................................................................................................... 18
4.1 Background ............................................................................................................. 18
4.2 Rationale for the Proposed Study ............................................................................. 20
4.3 Benefit/Risk Profile .................................................................................................21
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 22
5.1 Object ives................................................................................................................ 22
5.1.1 Primary Object ive.............................................................................................. 22
5.1.2 Secondary  Object ives......................................................................................... 22
5.1.3 Exploratory  Objectives ....................................................................................... 22
5.2 Endpoints ................................................................................................................. 22
5.2.1 Primary Endpo int............................................................................................... 22
5.2.2 Secondary  Endpo ints.......................................................................................... 22
5.2.3 Safety Endpo ints................................................................................................ 23
5.2.4 Exploratory  Endpo ints....................................................................................... 23
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 24
6.1 Study  Design ........................................................................................................... 24
6.2 Justification for Study Design, Dose, and Endpoints ................................................ 28
6.3 Prem ature Terminat ion or Suspension o f Study  or Study  Site................................... 28
6.3.1 Criteria for Premature Terminat ion or Suspension of the Study .......................... 28
6.3.2 Criteria for Premature Terminat ion or Suspension of Study  Sites....................... 29
6.3.3 Procedures for Premature Termination or Suspension of the Study  or the 
Parti cipation of  Study  Site(s).............................................................................. 29
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 30
7.1 Inclusio n Cri teria..................................................................................................... 30
7.2 Exclusio n Cri teria.................................................................................................... 30
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 7of 86
Protocol Incorporating Amendment No. 05 19 December 2018
7.3 Excluded Medicat ions.............................................................................................. 31
7.4 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 32
7.5 Procedures for D iscont inuat ion or Withdrawal o f a Subject ...................................... 33
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 34
8.1 Study  Drug and Materials ........................................................................................ 34
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling ..................................... 34
8.1.1.1 TAK -954 .................................................................................................34
8.1.1.2 Ancillary  Materi als.................................................................................. 34
8.1.2 Storage ............................................................................................................... 34
8.1.3 Dose and Regimen ............................................................................................. 34
8.1.4 Overdose ............................................................................................................ 35
8.2 Study  Drug Assignment and Dispensing Procedures ................................................ 35
8.3 Randomization Code Creation and Storage .............................................................. 35
8.4 Study  Drug Blind Maintenance ................................................................................ 35
8.5 Unblinding Procedure .............................................................................................. 35
8.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 36
9.0 STUDY PLAN .............................................................................................................. 37
9.1 Study  Procedures ..................................................................................................... 37
9.1.1 Informed Consent Procedure .............................................................................. 37
9.1.2 Dem ographics, Medi cal History , and Medicat ion History  Procedure .................. 37
9.1.3 Physical Examinat ion Procedure ........................................................................ 37
9.1.4 Weight, Height and BMI .................................................................................... 37
9.1.5 Vital Sign Procedure .......................................................................................... 38
9.1.6 Docum entati on of  Conco mitant Medi cations...................................................... 38
9.1.7 Docum entati on of  Concurrent Medi cal Condit ions............................................. 38
9.1.8 Procedures for Clinical Laboratory  Samples ....................................................... 38
9.1.9 Contraception and Pregnancy Avo idance Procedure ........................................... 40
9.1.9.1 Male Subjects and Their Female Partners ................................................ 40
9.1.9.2 Female Subjects and Their Male Partners ................................................ 40
9.1.9.3 Definit ions and Procedures for Contraception and Pregnancy Avoidance .41
9.1.9.4 General Guidance Wit h Respect to the Avo idance of Pregnancy .............. 43
9.1.10 Pregnancy .......................................................................................................... 43
9.1.11 ECG Procedure .................................................................................................. 43
9.1.12 Scint igraphy Procedure ...................................................................................... 44
9.1.13 Pharmacogeno mic and Bio marker Sample Co llection........................................ 45
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 8of 86
Protocol Incorporating Amendment No. 05 19 December 2018
9.1.13.1 Biomarker Sam ple Collect ion.................................................................. 45
9.1.14 PK Sam ple Collect ion and Analysis ................................................................... 46
9.1.14.1 Collect ion of Plasma for PK Sampling ..................................................... 46
9.1.15 Docum entati on of  Screen Failure ....................................................................... 47
9.1.16 Docum entati on of  Rando mization ...................................................................... 47
9.1.17 Blood Vol ume.................................................................................................... 48
9.2 Moni toring Subject Treatment Compliance .............................................................. 48
9.3 Schedule of Observat ions and Procedures ................................................................ 48
9.4 Biological Sample Retent ion and Destruction .......................................................... 48
10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................ 50
10.1 Definit ions............................................................................................................... 50
10.1.1 PTEs .................................................................................................................. 50
10.1.2 AEs.................................................................................................................... 50
10.1.3 Addit ional Po ints to Consider for PTEs and AEs ................................................ 50
10.1.4 SAEs .................................................................................................................. 52
10.1.5 Management of Specific AEs ............................................................................. 53
10.1.5.1 Cardi ovascular Disorders ......................................................................... 53
10.1.5.2 Serotonin Syndrome ................................................................................ 55
10.1.5.3 AESI ....................................................................................................... 55
10.1.6 Intensit y of PTEs and AEs ................................................................................. 55
10.1.7 Causalit y of AEs................................................................................................ 56
10.1.8Relationship to Study  Procedures ....................................................................... 56
10.1.9 Start Date ........................................................................................................... 56
10.1.10 Stop Date ..................................................................................................... 56
10.1.11 Frequency .................................................................................................... 56
10.1.12 Action Concerning Study  Drug .................................................................... 56
10.1.13 Outcom e....................................................................................................... 57
10.2 Procedures ............................................................................................................... 57
10.2.1 Collect ion and Reporti ng of AEs........................................................................ 57
10.2.1.1 PTE and AE Collection Period .................................................................57
10.2.1.2 PTE and AE Reporting ............................................................................ 57
10.2.1.3 AEs of Special Interest ............................................................................ 58
10.2.2 Collect ion and Reporti ng of SAEs ...................................................................... 58
10.2.3 Reporting of Abnormal LFTs ............................................................................. 59
10.3 Follow-up of  SAEs .................................................................................................. 59
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 9of 86
Protocol Incorporating Amendment No. 05 19 December 2018
10.3.1 Safety Reporting to Invest igators, IRBs, and Regulatory  Authori ties.................. 59
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 60
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 61
12.1 CRFs (El ectronic and Paper) .................................................................................... 61
12.2 Record Retention ..................................................................................................... 61
13.0 STATISTICAL METHODS .......................................................................................... 63
13.1 Statistical and Analyt ical Plans ................................................................................ 63
13.1.1 Analysis Sets ...................................................................................................... 63
13.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 63
13.1.3 Pharmacokinet ic Analysis .................................................................................. 63
13.1.4 PD Analysis ....................................................................................................... 64
13.1.5 Biomarkers ........................................................................................................ 65
13.1.6 Safety Analysis .................................................................................................. 65
13.1.7 Other Analyses ................................................................................................... 65
13.2 Interim Analysis and Criteria for Early Terminat ion................................................ 65
13.3 Determinat ion of Sample Size .................................................................................. 66
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 67
14.1 Study -Site Moni toring Visit s................................................................................... 67
14.2 Protocol  Deviat ions.................................................................................................. 67
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 67
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 68
15.1 IRB.......................................................................................................................... 68
15.2 Subject Informa tion, Inform ed Consent, and Subject Authorizat ion......................... 68
15.3 Subject Confidentialit y............................................................................................ 70
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................70
15.4.1 Publicat ion and Disclosure ................................................................................. 70
15.4.2 Clinical Trial Registration .................................................................................. 70
15.4.3 Clinical Trial Result s Disclosure ........................................................................ 71
15.5 Insurance and Co mpensation for Injury .................................................................... 71
16.0 REFERENCES .............................................................................................................. 72
LIST OF IN -TEXT TABLES
Table 7.a Excluded Medicat ions........................................................................................ 32
Table 9.a Clinical Laboratory  Tests ................................................................................... 39
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 10of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Table 9.b Primary Specimen Collections ........................................................................... 47
Table 10.a Takeda Medically Significant AE List ................................................................ 53
Table 13.a Summary  of Detectable Effect Sizes for PD Endpoints ....................................... 66
LIST OF IN -TEXT FIGURES
Figure 6.a Schemat ic of Study  Design ................................................................................ 25
LIST OF APPENDICES
Appendix A Schedule of Study  Procedures ............................................................................ 73
Appendix BResponsibilit ies o f the Invest igator ..................................................................... 75
Appendix C Elements of the Subject Informed Consent ......................................................... 77
Appendix D Invest igator Consent to Use of Personal Inf ormation.......................................... 80
Appendix E Hepati c Funct ion Categories Based on Child -Pugh Score ................................... 81
Appendix F Detailed Descript ions of Amendments to Text ................................................... 82
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 11of 86
Protocol Incorporating Amendment No. 05 19 December 2018
2.0 STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Americas, Inc. Compound:
TAK -954
Title of Protocol: A Dose -Ranging, Randomized, Parallel, 
Placebo -Controlled Study to Assess the Effect of TAK -954 
on Gastrointestinal and Colonic Transit in Patients With 
Diabetic or Idiopathic GastroparesisIND No.: 114408 EudraCT No.:
Not applicable
Study Number: 2003 Phase: 2a
Study Design:
This is a phase 2a, dose -ranging, randomized, parallel group, double -blind, placebo -controlled study evaluating the 
effects of TAK -954 on gastrointestinal (GI) and colonic transit in diabetic subjects reporting symptoms of 
gastropa resis with previously documented delay in gastric emptying or in subjects with diagnosis of idiopathic 
gastroparesis. The study will evaluate 12 subjects per treatment group. 
This study consists of 3 periods and a Follow -up: a Screening Visit, a Baseline Period (between Day -14 and 
Day -1), Treatment Period (Days 1 to 4), and Follow -up Phone Call (Days 10 to 14). 
Subjects will have an initial Screening Visit, then will undergo a baseline gastric emptying assessment with 
scintigraphy scans acquired at 0, 1, 2, 3 and 4 hours after radiolabeled meal, between Day -14 and Day -1 (Baseline 
Visit). The Screening and Baseline Visits may be performed on the same day.
If eligibility criteria are fulfilled, subjects will be randomized on Day 1 to TAK -954 0.1, 0.3, o r 1 mg, or placebo. 
Based upon the results of the preplanned interim analysis, the number of active treatment arms has been decreased 
from 3 to 2. The specific dose deleted is not specified in order to maintain the blind of the study team. This change 
was not necessitated by safety findings.
Subjects will receive TAK -954 or placebo as a 60 -minute intravenous (IV) infusion (at any time in the morning 
prior to 12:00) once a day for 3 days starting on Day 1. Following the infusion on Day 2, subjects will under go 
scintigraphic assessment of gastric, small bowel, and colonic transit of solids over a 48 -hour time period while on 
treatment.
The subjects will have pharmacokinetic (PK) samples collected as follows:
Day 1: prior to dosing (0 hour), 1 (end of infusion) , 2, and 4 hours after start of infusion. 
Day 2: prior to dosing (0 hour), 1 (end of infusion), 2, 5, 7, and 9 hours after the start of the infusion. 
Day 3: prior to dosing (0 hour), 1 (end of infusion) and 2 hours after start of infusion.
Day 4: 25 hour s after the start of the infusion on Day 3 (48 hours after the administration of the radiolabeled 
meal on Day 2, same time as the 48- hour geometric center measurement).
All participating subjects will have a 6 -hour Holter monitor placed at the Baseline Vis it. On Day 1, subjects will 
have continuous monitoring with a Holter monitor which will be placed prior to the first dose until the morning of 
Day 3. 12 -lead ECG will be performed on Days 1, 2, and 3 prior to each IV infusion; within 30 minutes postinfusio n 
and prior to discharge; and at the Final Visit on Day 4 or Early Termination Visit. In addition, a 12 -lead ECG will be 
performed when needed, if a subject develops symptoms or clinical signs suggestive of cardiovascular origin (eg, 
dizziness, lightheaded ness, chest pain, chest heaviness, palpitations, shortness of breath, tachycardia).
During the study, subjects will complete a daily diary to record their bowel habits. The subjects will assess their 
global GI symptom score using the GCSI at Screening. The On-study Bowel Habit Diary Card will be dispensed at 
Screening, to be completed daily from Screening and through the Treatment Period. The completed Bowel Habit 
Diary  Card will be collected at the conclusion of the study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 12of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Primary Objective:
To evaluate the dose -dependent effects of TAK -954 on gastric emptying time of solids in subjects with diabetic or 
idiopathic gastroparesis assessed by scintigraphy.
Secondary Objectives:
1.To evaluate the PD effects of TAK -954 o n intestinal and colonic transit time ass essed by scintigraphy.
2.To evaluate the PK of TAK -954 in subjects with gastroparesis.
3.To assess the safety and tolerability of multiple doses of TAK -954.
Subject Population: Diabetic subjects reporting symptoms of gastroparesis with a previously documented delay in 
stomach emptying or subjects with a diagnosis of idiopathic gastroparesis.
Number of Subjects:
Approximately 36 to 41 subjects (maximum of 12 per 
group)Number of Sites: 
Estimated total: 1 site in the United States
Dose Level(s):
TAK -954 0.1, 0.3, and 1 mg once daily (QD)
PlaceboRoute of Administration:
TAK -954 (IV)
Placebo (IV)
Duration of Treatment:
3 day sPeriod of Evaluation:
Up to 28 days
Main Criteria for Inclusion: 
Males and nonpregnant, nonbreastfeeding females who are aged 18 to 65 years, inclusive, with a body mass index 
(BMI) ≥16 and ≤40 kg/m2. Subjects must have diabetes mellitus with symptoms of gastroparesis and previously 
documented gastric emptying delay or previously documented idiopathic gastroparesis in the last 5 years. 
Main Criteria for Exclusion:
Subjects who:
Have gly cosylated hemoglobin (HbA1c) >12%.
Have other structural diseases/conditions that affect the GI system.
Are unable to withdraw drugs known to alter GI transit 48 hours prior to the study.
Have clinically significant abnormal baseline safety labs.
Have clinical evidence of significant cardiovascular, respirator y, moderate or severe renal insufficiency, 
hematological, neurological, or psychiatric disease, or other disease that interferes with the objectives of the 
study. 
Have preexisting hepatic disease that meets Child -Pugh Class B (moderate; total score 7 to 9 points) or C 
(severe; total score 10 to 15 points), see Appendix E.
Are without known preexisting hepatic disease who have 1 or more of the following:
AST or ALT >2 times the ULN.
Bilirubin >1.5 times the ULN unless due to Gilbert’s syndrome.
International normalized ratio (INR) >1.5 unless on ant icoagulation therapy.
Have QTcF (QT interval with Fredericia correction method) interval ≥460 msec or with other factors that 
increase the risk of QT prolongation or arrhythmic events at screening. Note: Subjects with bundle branch block 
and a prolonged QT c interval, or with QTcF between 450 and 460 msec, should be reviewed by the medical 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 13of 86
Protocol Incorporating Amendment No. 05 19 December 2018
monitor for potential inclusion.
Have cardiac history that includes conditions requiring heart rate control (eg, atrial fibrillation, atrial flutter). 
Have second or third degree atrioventricular (AV) block; AV disassociation; >5 beats of non -sustained VT at a 
rate >120 bpm; ECG changes consistent with acute myocardial ischemia or infarction.
If female, are pregnant or lactating or intending to become pregnant before p articipating in this study, during the 
study, and 4 to 5 days (5 half -lives) PLUS 30 days after last dose of the study drug; or intending to donate ova 
during such time period.
Are considered by the investigator to be alcoholics not in remission or known s ubstance abusers. Have a history 
of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to: 
beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce] per day).
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is half -empty ing time (T 1/2)of gastric emptying of solids.
The secondary endpoints for this study are:
Colonic geometric center at 4, 24, and 48 hours after radiolabeled meal.
Colonic filli ng at 6 hours (measure of small bowel transit time) after radiolabeled meal.
T1/2of ascending colon emptying.
The plasma PK parameters (area under the concentration -time curve during a dosing interval [AUC τ], maximum 
observed concentration [C max], and observed concentration at the end of a dosing interval [C trough]) of 
TAK -954.
The safety endpoints for this study are:
The percentage of subjects who experience at least 1 treatment -emergent adverse event. 
The percentage of subjects who discontinue due to an adverse event (AE). 
The incidence of subjects who meet the markedly abnormal criteria for safety laboratory tests postdose. 
The incidence of subjects who meet the markedly abnormal criteria for vital s ign measurements postdose.
The percentage of subjects who meet the markedly abnormal criteria for safety 12 -lead ECG parameters and 
Holter monitor postdose.
Statistical Considerations:
The effects of the TAK -954 treatment on the primary PD endpoint will b e assessed using analysis of covariance 
(ANCOVA). The secondary response measures will also be assessed using ANCOVA (with suitable transformation 
for skewness in the distributions of measured volumes), and, if necessary, nonparametric methods will be used . The 
covariates considered for inclusion in the analyses will be age, gender, BMI, and the baseline measurement of the 
respective PD measure. Two -sided 95% CI will be presented for the comparison of each dose of TAK -954 against 
placebo, both multiplicity adjusted and unadjusted CIs will be presented. 
Information on the global score using the GCSI, as well as bowel movement frequency per day and average stool 
consistency on the Bristol stool form scale, will be tabulated and analyzed respectively. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 14of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Sample Size Justification: Below summarizes data for the primary and secondary PD response measures and uses 
the (relative) percent coefficient of variation, (%CV) to estimate the effect size detectable with 80% power based on 
a 2 sample z -test (ie, assuming the variation values are known) at a two -sided alpha level of 0.05. The effect size is 
the difference in group means as a percentage of the overall mean for each response and assumes 12 subjects per 
group. The ANCOVA should provide 80% power to detect similar (pairwise) differences using a pooled estimate of 
variation across all 3 groups and potentially even smaller effect sizes by adjusting for important covariates. An 
effect size of at least 30% for the primary endpoint is considered to be clinically importa nt. The data from the 
scintigraphic transit studies are unpublished but based on the same methods proposed for this study.
Assuming n=12/Group 4 -GROUP DESIGN (Based on ANCOVA α=0.05)
Response Type Mean SD %CVEffect Size (%)
Detectable with 80%
Power ( =0.05)
Gastric emptying of solids T 1/2min 
(N=319)122 29.8 24.5 34.2
Colonic filling at 6 h, % (N=63) 44 29 66 79
Geometric center at 24 h (N=220) 2.4 0.9 36 52
Ascending colon T 1/2h (N=50) 15.0 8.0 53 63
An interim analysis was conducted when approximately half of the subjects have completed the study. Efficacy and 
safety data was reviewed to determine if the study should be modified based on the interim analysis results. 
An executive committee within Takeda composed of a senior clinician, a senior statistician, a senior clinical 
pharmacologist, and a senior pharmacovigilance scientist not involved in the study have reviewed the interim 
analy sis results and made recommendations for changes to the study. Al l members of the study team and the 
investigative team will remain blinded to treatment arm assignment and treatment arm results until the completion of 
the study .
Based upon the results of the preplanned interim analysis, 1 of the TAK -954 doses was droppe d. The specific dose 
dropped is not specified in order to maintain the blind of the study team. The sample size for the remaining 
treatment arms will not change.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 15of 86
Protocol Incorporating Amendment No. 05 19 December 2018
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
clinical supplier list in the study  manual . The identified vendors will perform specific 
study -related activit ies either in full  or in partnership wi th the sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 16of 86
Protocol Incorporating Amendment No. 05 19 December 2018
3.2 List of Abbreviation s
5HT4 serotonin
99mTc technetium -99m
111In indium chloride isotope
AC ascending
AE adverse event
ALT alanine aminotransferase
ANCOVA analy sis of covariance
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC 24 area under the concentration -time curve from time 0 to 24 hours
AUC 24,ss area under the concentration -time curve from time 0 to time 24, at steady state
AUC τ area under the concentration -time curve during a dosing interval
AV atrioventricular
BP blood pressure
BMI body mass index
%CV percent coefficient of variation
Cmax maximum observed concentration
Cmax,ss maximum observed concentration during a dosing interval, at steady state
Ctrough observed concentration at the end of a dosing interval
CYP cytochrome P450
DC Descending colon
eCRF electronic case report form
ECG electrocardiogram
EFI enteral feeding intolerance
FAS full analy sis set
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GCSI Gastroparesis Cardinal Symptom Index 
GGT γ-glutamyl transferase
GI gastrointestinal
HbA1c glycosylated hemoglobin
hCG human chorionic gonadotropin
HR heart rate
ICH International Conference on Harmonisation
ICU intensive care unit
INR internatio nal no rmalized ratio
IRB institutional review board
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
CCI
TAK -954
Study No. TAK -954-2003 Page 17of 86
Protocol Incorporating Amendment No. 05 19 December 2018
IUD intrauterine device
IV intravenous
kcal kilocalorie 
LFT(s) liver function test(s)
MTD maximum tolerated dose
MedDRA Medical Dictionary for Regulatory Activities
NOAEL no-observed -adverse -effect level
NOEL no-observed -effect -level
PD pharmacodynamic(s)
PGx pharmacogenomic(s)
PK pharmacokinetic(s)
PPS per protocol set
RS rectosigmoid colon
PTE pretreatment event
QD once daily
QTc corrected QT interval
QTcF QT interval with Fridericia correction method
SAE serious adverse event
SUSARs suspected unexpected serious adverse reactions
SVT supraventricular tachycardia
T1/2 half-empty ing time
TC transverse colon
ULN upper limit of normal
VT ventricular tachycardia
3.3 Corporate Identification
TDC Americas Takeda Development Center Americas , Inc.
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda TDC Japan, TDC Asia, TDC Europe and/o r TDC Americas, as applicable
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 18of 86
Protocol Incorporating Amendment No. 05 19 December 2018
4.0 INTRODUCTION
4.1 Background
TAK -954 i s a highly selective and potent 5 -HT 4receptor agonist that has shown prokinetic 
activit y throughout the gastrointestinal (GI) tract in experimental models and is in development 
for shor t-term (acute) use in the treatment of crit ically ill pati ents wi th enteral  feeding intol erance 
(EFI). Crit ically ill pat ients who require enteral feeding frequent ly have reduced GI motilit y 
including delayed gastric empt ying, develop enteral feeding intol erance, which can lead to 
several co mplications including not meet ing daily calorie and protein requirements [1]. 
Malnutri tion in these pat ients is associ ated wi th impai rment of immuno logical funct ion, 
increased risk of infect ion, prolongat ion of mechanical vent ilation, increased length of intensive 
care unit and hospital stay , and ul timately higher mortalit y [
2,3].
Nonclinical studies complet ed to date include intravenous (IV) and oral single -dose studi es in 
rats, oral single -dose studi es in dogs, and oral 28
-day and 13 -week repeat -dose studies in rats and 
dogs. TAK -954 was also tested in vitro and in vivo  genotoxicit y studi es, embry o-fetal toxicity 
studi es in rats and rabbits, and ex vivo and in vivo local tolerance studies. Toxicokinet ic analysis 
of TAK -954 pl asma l evels was conducted in the Good Laboratory  Practi ce repeat -dose studies. 
Studi es of TAK -954 on central  nervous sy stem  and respi ration showed no effect at clinically 
relevant doses. In the cardiovascular safet y pharmacology  study  in dogs, dose -dependent 
increases in mean heart rate (HR) and non -dose-dependent increases in diastolic blood pressure 
and mean arterial blood pressure wer e observed (61- fold margin at dog no -observed -effect l evel 
(NOEL) versus healthy human maximum observed concentration [C max] at 1 m g, IV 
[extrapol ation based on 2x0.5 m g, IV pharm acokineti cs (PK); assumes linear PK between 
0.5and 1 mg dose]). 
TAK -954 i s a substrate of cy tochrom e P450 (CYP) 3A4, CYP2D6, CYP2C9/19, and 
P-glycoprotein. TAK -954 had no si gnificant inhibitory  effect on the activit ies of major human 
CYPs 1A2, 2C9, 2C19, 2D6, and 3A in human liver microsomes. No inhibitory  effect of the 
metabo lites, THRX -513466 and THRX -913682, were observed on the metabo lic activit ies of 
CYP1A2, CYP2C19, and CYP3A, and only  moderate inhibi tion (up to 42%) was observed on 
the metabo lic activit ies of CYP2C9 and CYP2D6 at high TAK -954 concentrations of 10 µM. 
TAK -954 i s moderately  protein bound, exhibit ing concentration -independent binding.
In repeat -dose toxicit y studies, the key  adverse findings attributed to TAK -954 administration 
were decreased body  weight gains and food consumpt ion at hi gher doses in rats, dogs, and 
rabbits, effects that were dose -limit ing in these species. In the 13 -week dog study , an 
approximately  10.5% increase in the QT interval with Fridericia correction method (QTcF) was 
noted only on Day  28 in males receiving 30 mg/kg/day  (160 -fold margin at dog NOEL at 
10mg/kg/day versus healt hy human C maxat 1 m g, IV [extrapolat ion based on 2x0.5 mg, IV 
Cmax]). Other notable effects of TAK -954 observed in the rat toxicit y studi es included 
phospho lipidosis in the lung and vacuo les in scattered thy roid follicular cells o f rats, and 
vacuo lated m acrophages in the spleen and an increase in the degree of mammary  gland 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 19of 86
Protocol Incorporating Amendment No. 05 19 December 2018
development in female rats; these findings were all reversible but did not reach full reso lution at 
the end of the recovery  period (468 -fold marg in at rat no -observed -adverse -effect level 
[NOAEL] versus healt hy human area under the concentration -time curve fro m 0 to 24 hours 
[AUC 24] at 1 m g, IV [extrapolat ion based on 2x0.5 mg, IV AUC 24]). TAK -954 di d not exhibit 
genotoxi c potenti al. The embry o-fetal toxicity studies in rats and rabbits demonstrated embry o-
fetal effects characterized by  lower fetal  weights and increased skeletal variat ions (decreased 
ossification) limited to maternally toxic doses (250 -fold margin at rabbit NOAEL versus healt hy 
huma n AUC 24at 1 m g, IV [extrapol ation based on 2x0.5 mg, IV AUC 24]).
TAK -954 was well -tolerated in local tolerance studies at concentrations up to 20 µg/mL and did 
not cause hemo lysis or flocculat ion in rat, dog, or human who le blood. 
TAK -954 has been evaluated in 4 clinical studies to date: 3 phase 1 studies in healthy subjects, 
and an exploratory  phase 2 study  in critically  ill pati ents wi th enteral  feeding intol erance (EFI).
After single ascending oral doses (0.1 to 20 mg) of TAK -954 in healt hy subjects, the m aximum  
tolerated dose (MTD) dose was 10 mg and resulted in a C maxof 94.4 ng/mL and area under the 
concentration time -curve from  time 0 to infinit y of 1017 ng•hr/mL. After mult iple ascending oral 
doses (0.2 to 10 mg) once daily (QD) of TAK -954 i n healthy subjects, the MTD dose was 5 mg 
and resulted in a maximum observed concentration during a dosing interval, at steady  state 
(Cmax,ss) of 27.72 ng/m L and area under the concentration -time curve from 0 to 24 hours at 
steady  state (AUC 24,ss)of 386.5 15 ng•hr/mL. C maxand the area under the concentration- time 
curve (AUC) increased in a roughly  dose -proportional  manner. TAK -954 was not extensively  
converted to either metabo lite (THRX -513466 or THRX -913682), as assessed by circulat ing 
levels in plasma an d urine.
After m ultiple daily IV infusio n dosing in healt hy subjects, mean TAK -954 C max,ss was 7.07 and 
7.6 ng/m L in Cohorts 1 (0.5 mg QD over 5 days) and 2 (0.1 mg on Day  1 and 0.5 m g QD Days 2 
to 5), respectively . Mean TAK -954 AUC 24,sswas 51.0 and 63.3 ng.h/mL in Cohorts 1 and 2, 
respectively . TAK -954 steady  state was achi eved by  Day  3, wi th mean half -life (t 1/2) values 
ranging from 18.0 to 18.9 hours on Day  5. The increase in Day  1 exposure from  the 0.1 to 
0.5mg IV dose was approximately dose proportional. Based on the principle o f superposi tion, 
the predicted C max,ss and AUC 24,ssfor TAK -954 1 mg IV dosing were 15.2 ng/mL and 
126.6 ng.h/mL, respectively, which are approximately 2 to 3 -fold lower com paring to m ultiple 
oral doses of 5 mg. The mean amount of TAK -954 excreted unchanged in urine on Day  5 ranged 
from 27.7% to 31.6%. In subjects who were critically  ill and received 0.5 mg by IV infusio n, the 
PK exposure was approximately 30% lower to that observed in healt hy subjects.
After m ultiple oral  doses in healthy subjects, TAK -954 was generally well tolerated at doses up 
to 5 m g QD f or 10 days. There were no serious adverse events (SAEs) and the overall incidence 
of adverse events (AEs) reported for the TAK -954 dose groups was similar to that for the 
placebo group. All AEs were mild or moderate. The most commonly reported treatment -related 
AEs in TAK -954 subjects overall were headache and diarrhea. No dose -related trends were 
evident in the AE data across the 0.2, 1, or 5 mg dose groups, but 2 of 3 subje cts receiving 10 m g 
were di scont inued because of an AE (mild intermittent atrioventricular dissociat ion which 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 20of 86
Protocol Incorporating Amendment No. 05 19 December 2018
resolved wit hout intervent ion). There were no safety  signals in the clinical laboratory  or 
respi ratory  rate data after mult iple dose administratio n. Mean blood pressure (BP) and HR 
remained in the normal range for all groups throughout the study . However, there was a trend 
toward lower BP and elevated HR in the standing posit ion for TAK -954 subjects, but no dose 
response was apparent. In addit ion, there was 1 AE related to BP (orthostatic hypotension in a 
subject who received 5 mg TAK- 954).
Evidence of GI proki netic activit y in healt hy subjects (increased bowel movement frequency , 
looser stool  consistency , and decreased t ime to first bowel movement) was observed at all dose 
levels after receiving single and mult iple doses (oral and IV). In 7 subjects who were crit ically 
ill, scint igraphy  data quali tatively  suggested TAK -954 decreases gastric empt ying time fo llowing 
a liquid meal .
The purpose of this dose-ranging, rando mized, parallel group, double -blind, pl acebo -controlled 
study  is to eval uate the pharmacodynamic (PD) effects of TAK -954 on gastri c, intestinal, and 
colonic transi t in diabet ic subjects reporting symptoms of gastroparesis with previously
docum ented del ay in stom ach em ptying, or in subjects with a diagnosis of idiopathic 
gastroparesi s.
Please refer to the TAK -954 Invest igator’s Brochure for complete informat ion on the 
investigat ional product.
This study  will be conducted in com pliance wi th the protocol , Good Clinical Practice (GCP), and 
the applicable regulatory  requi rements.
4.2 Rationale for the Proposed Study
Gastroparesis is a syndrome characterized by  delayed gastri c emptying in the absence of 
mechanical obstruction of the stomach. The car dinal  symptom s include postprandial fullness 
(early  satiety ), nausea, vo miting, pain, and blo ating. Gastroparesis occurs in several clinical 
settings, particularly as a co mplication o f diabetes mellitus, but also as a complication of upper 
GI surgery , neur ological disease, collagen vascular disorders, viral infect ions, drugs, and so on. 
In the m ajority of cases, no underlying cause is found and gastroparesis is termed idiopathic. 
Several abnormalit ies in diabetes might result in gastric motor dy sfunct ion including autonomic 
neuropathy , enteri c neuropathy  involving excitatory and inhibitory  nerves, abnorm alities of the 
interstitial cells o f Cajal and acute fluctuations in blood glucose amo ng others [4]. 
The underlying mechanism o f delayed g astric em ptying is commo n to both patients with 
gastroparesi s and EFI, and the same products have been successfully studied and utilized in both 
popul ations to promote gastric empt ying. This study  will evaluate the prokinet ic effect of 
TAK -954 on gastri c emptying, intestinal and colonic transit in subjects with previously 
docum ented del ay in gastri c empt ying.
Phase 1 studies have demo nstrated acceptable PK characterist ics and TAK -954 was well 
tolerated at all doses studied in the co mpleted phase 1 and 2a st udies. The TAK -954 IV doses to 
be used in the study , 0.1, 0.3 and 1 m g, were sel ected based on safet y, tolerabilit y, PK, and PD 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 21of 86
Protocol Incorporating Amendment No. 05 19 December 2018
(bowel  movement, gastri c em ptying time, and HR) data from the healt hy and crit ically ill subject 
studi es. Based on a TAK -954 pre liminary populat ion-PK m odel using data from Phase 1 studies 
and in -vitro receptor saturati on data, predicted subjects’ trough 5 -HT 4receptor occupancy at 
steady  state is est imated to be approximately 30%, 50% and 80% for 0.1, 0.3 and 1 mg doses, 
respectively . The dose range, 0.1, 0.3 and 1 mg, is expected to span the anticipated 
pharmaco logically act ive dose range and is potentially considered well wit hin the safet y margin.
4.3 Benefit/Risk Profile 
There i s no expected clinical benefit to the study  parti cipants. Potential risk s are based on 
TAK -954 clinical findings, the mechanism o f action, nonclinical findings and the route of 
administration. The study  involves the use of radiation that is within limit s permissible for 
healt hy vo lunteers and hence patients.
Also, there is min imal risk associated with study  procedures including scheduled, periodic 
phlebotomy  (limi ted to <500 mL) and noninvasive procedures including vital sign assessments 
and electrocardiograms (ECGs). The principal mit igation for these ri sks includes appropriat e 
select ion of the study  popul ations, the Clinical Research and Trials Unit setting, which permit s 
close m onitoring and rapi d inst itution of  appropri ate care as needed, appropriate specified 
monitoring procedures, and utilization o f experienced staff train ed in study  procedures. Overall, 
the risk:benefit profile is considered appropriate for this study .
Property of Takeda: For non-commercial use only and e Terms of Use
CCI
TAK -954
Study No. TAK -954-2003 Page 22of 86
Protocol Incorporating Amendment No. 05 19 December 2018
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objective
The primary  object ive of this study  is to eval uate the dose -dependent effects of TAK -954 on 
gastric empt ying time of so lids in subjects wi th diabetic or idiopathic gastroparesis assessed by 
scint igraphy.
5.1.2 Secondary Objectives
The secondary  objectives of this study  are to:
Evaluate the PD effects of TAK- 954 on intestinal and co lonic transit time assess ed by  
scint igraphy.
Evaluate PK of TAK -954 in subjects with gastroparesis.
Assess the safet y and tol erabilit y of mult iple doses of TAK-954.
5.1.3 Exploratory Objectives
5.2 Endpoints
5.2.1 Primary Endpoint
The primary  endpoint for thi s study  is half -empt ying time (T1/2)of gastri c empt ying of so lids.
5.2.2 Secondary Endpoints
The secondary  endpoints for this study  are: 
Colonic geom etric center at 4, 24, and 48 hours after the radio labeled meal.
Colonic filling at 6 hours (measure of small bowel transit time) after the radiolabeled meal.
Property of Takeda: and subject to the applicable Terms of Use
CCI
TAK -954
Study No. TAK -954-2003 Page 23of 86
Protocol Incorporating Amendment No. 05 19 December 2018
T1/2of ascending colon empt ying.
The fo llowing PK parameters of TAK -954:
–Area under the concentration -time curve during a dosing interval (AUC τ), Cmax, and
observed concentration at the end of a dosing interval (C trough).
5.2.3 Safety Endpoints
The safet y endpo ints for thi s study  are:
The percentage of subjects who experience at least 1 treatment -emergent adverse event. 
The percentage of subjects who discont inue due to an AE. 
The incidence of subjects who meet the markedly  abnorm al criteria f or safety  laboratory  tests 
postdose. 
The incidence of subjects who meet the markedly  abnorm al criteria f or vital sign m easurements
postdose.
The percentage of subjects who meet the markedly abnormal criteria for safet y 12-lead ECG 
param eters and Holter m onitor postdose.
5.2.4 Exploratory Endpoints
Property of Takeda: For n nly and subject to the applicable Terms of Use
CCI
TAK -954
Study No. TAK -954-2003 Page 24of 86
Protocol Incorporating Amendment No. 05 19 December 2018
6.0 STUDY DESIGN AND DESCRIPTI ON
6.1 Study Design
This is a phase 2a dose -ranging, rando mized, parallel group, double -blind, placebo -controlled 
study  evaluat ing the effects of TAK -954 on gastri c, small bowel , and col onic transi t in diabetic 
subjects reporting symptoms o f gastroparesi s with previ ously docum ented delay  in stom ach 
emptying or in subjects with diagnosis of idiopathic gastroparesis. Twelve subjects per treatment 
group in diabet ic subjects with symptoms of gastroparesis and previously documented delay in 
stom ach em ptying or in subjects with diagnosis of idiopathic gastroparesis will be evaluated. 
This study  consists of 3 periods and a Follow -up: a Screening Period, Baseline Period (between 
Day -14 and Day  -1), Treatm ent Peri od (Day s 1 to 4), and a Follow -up Phone Call (Days10 -
14). Wom en of childbearing potential will receive an addit ional Follow-up Phone Call 
(Day s 38- 43). 
Subjects will have an init ial Screening Visit, then will undergo a baseline gastric empt ying 
assessment with scint igraphy scans acquire d at 0, 1, 2, 3, and 4 hours after radiolabeled meal, 
between Day  
-14 and Day  -1 (Baseline Visit). The Screening and Baseline Visits may  be 
perform ed on the sam e day. Wi thin 48 hours prior to baseline scint igraphy , female subjects m ust 
have a negat ive preg nancy  test. 
If eligibilit y criteria are fulfilled, subjects will be rando mized on Day 1 to TAK -954 0.1, 0.3, or 1 
mg, or pl acebo. Subj ects will receive TAK -954 or pl acebo as a 60 -minute intravenous (IV) 
infusio n (at any  time in the morning prior to 12:00) once a day  (QD) for 3 days starting on Day 
1. Following the TAK -954 infusio n on Day  2, subjects will undergo scint igraphic assessment of 
gastri c, small  bowel , and col onic transi t of solids during the Treatment Period.
At each visit, the fasting state of the subjects (8 hours) will be confirmed and fast ing (finger 
stick) bl ood gl ucose obtained. 
During the study , subjects will complete a daily diary  to record thei r bowel  habits. The subjects 
will assess their global GI symptom score using the GCSI at Screening. The On -Study  Bowel  
Habit Diary  Card will be dispensed at Screening to be completed daily  from Screening and 
through the Treatment Period. The completed Bowel Habit D iary Card will be collected at the 
concl usion of the study .
The subjects will have PK samples co llected as described in Sect ion 9.1.14.1 .
All participat ing subjects will have a 6 -hour Holter monitor placed at the Baseline Visit. On 
Day 1, subjects will have continuous ECG monitoring for up to 4 hours after the infusio n, and 
continuous monitoring with a Ho lter monitor whi ch will be placed prior to the first dose on 
Day 1 unt il the morning o f Day 3. 
Property of Takeda: For non-commerc  and subject to the applicable Terms of Use
CCI
TAK -954
Study No. TAK -954-2003 Page 25of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Parti cipants will undergo follow -up safet y monitoring by phone 7 -10 day s post l ast treatm ent 
dose. The study  will be considered com pleted after the last subject’s Fo llow-up Phone Call.
A schemat ic of the study  design is included as Figure 6.a. A schedule o f assessments is listed in 
Appendix A.
Figure 6.a Schematic of Study Design
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 26of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Figure 6.a Schematic of Study Design (continued)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 27of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Figure 6.a Schematic of Study Design (continued)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 28of 86
Protocol Incorporating Amendment No. 05 19 December 2018
6.2 Justification for Study Design, Dose, and Endpoints
The TAK -954 IV doses to be used in the study , 0.1, 0.3 and 1 m g, were sel ected based on safet y, 
tolerabilit y, PK and PD (bowel movement, gastric emptying time, HR) data from the healt hy and 
critically  ill subject studi es. Based on unbound TAK -954 pl asma concentrati ons using a 
preliminary populat ion-PK m odel and in -vitro receptor saturation, predicted subjects’ trough 
5-HT 4receptor occupancy at ste ady state are estimated to be approximately 30%, 50% and 80% 
for 0.1, 0.3 and 1 mg doses, respectively. The dose range, 0.1, 0.3 and 1 mg, is expected to span 
the ant icipated pharmaco logically act ive dose range and is considered well wit hin the safet y 
marg in.
Measurement of gastric emptying of so lids as measured by T 1/2 is endorsed by  national societ ies 
[
9]for use in clinical pract ice to ident ify gastric motor funct ion abnormalit ies as in condit ions 
associ ated wi th slow or accel erated gastri c em ptying, to invest igate pathophysio logical  
mechanis ms that may be associated with pat ients’ symptoms or syndromes, and to evaluate the 
effects of treatment such as prokinet ic agents [
4]. Therefore scint igraphy assessment of gastric 
emptying is the most appropriate tool to evaluate the pha rmacodynamic properties of TAK -954 
in upper GI motilit y and to assess its potential in both gastroparesis and enteral feeding 
intolerance. [4]
The study ’s secondary  endpoints include col onic geom etric center at 4, 24, and 48 as a measure 
of colonic transi t time and col onic filling at 6 hours as an indirect measure of intestinal transit 
time that will help to obtain a complete picture of the prokinet ic effect of TAK -954 by assessing 
its effects on the lower GI tract. This assessment is relev ant not only because it can help to 
evaluate TAK -954’s potenti al applicati on in other condit ions associated with delayed intestinal 
motility such as postoperative ileus, intest inal pseudo obstruction or constipation; but also 
because it can help to determi ne the ri ght dose for use in future trials in crit ically ill pat ients at 
high ri sk of  malnutri tion and EFI as accelerated bowel and colonic transit time can increase the 
risk of diarrhea and malabsorption.
6.3 Premature Termination or Suspension of Study or St udy Site
6.3.1 Criteria for Premature Termination or Suspension of the Study
The study  will be com pleted as pl anned unless 1 or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study .
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  drug that 
indicates a change in the known risk/benefit profile for the TAK -954, such that the risk is no 
longer acceptable for subjects participat ing in the study .
Significant vio lation of GCP that com promises the abilit y to achieve the primary study  
objectives or compromises subject safet y.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 29of 86
Protocol Incorporating Amendment No. 05 19 December 2018
6.3.2 Criteria for Premature Termination or Suspension of Study Sites
A study  site may be terminated prem aturely or suspended if the site (including the invest igator) 
is found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study , or as otherwise permitted by  the contractual  agreem ent.
6.3.3 Procedures for Premature Termination or Suspension of the Stud y or the 
Participation of Study Site(s)
In the event that the sponsor, an inst itutional review board (IRB) or regulatory  authori ty elects to 
terminate or suspend the study  or the parti cipat ion of a study  site, a study -specific procedure for 
early  terminat ion or suspensio n will be provided by  the sponsor; the procedure will be followed 
by applicable study  sites during the course of terminat ion or study  suspensi on.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 30of 86
Protocol Incorporating Amendment No. 05 19 December 2018
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results , need to be confirmed prior to randomizat ion. 
7.1 Inclusion Criteria
Subject eligibilit y is determined according to the following criteria prior to entry  into the study :
1.In the opinion o f the invest igator, the subject is capable of understanding and complyi ng wi th 
protocol  requi rements.
2.The subject or, when applicable, the subject’s legally acceptable representative signs and 
dates a wri tten, informed consent form and any  requi red privacy authorization prior to the 
initiation of any study  procedures. 
3.The su bject has diabetes mellitus with symptoms of gastroparesis and previously documented 
gastri c empt ying delay or previously documented idiopathic gastroparesis in the last 5 years.
4.The subject is a male or nonpregnant, nonbreast feeding female and aged 18 to 65 years, 
inclusive.
5.The subject has a body  mass index (BMI) ≥16 and ≤40 kg/m2at the Screening Visit. 
6.A female subject of childbearing potential* must agree to use highly  effect ive contraception 
during the course of the study . 
*Definit ions and highly  effective methods of contraception are defined in 
Secti on9.1.9 and reporting responsibilit ies are defined in Sect ion 9.1.10 .
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study : 
1.The subject has participated in another intervent ional clinical study  within the past 30 day s.
2.The subject is an immediate family member, investigat ional team member, or is in a 
dependent relat ionship with an invest igational team member who is invo lved in conduct of 
this study  (eg, spouse, parent, child, sibling) or may  consent under duress.
3.The subject has HbA1c >12%.
4.The subject has other structural diseases/condit ions that affect the GI sy stem .
5.The subject has a history  of hypersensi tivity or allergi es to TAK -954.
6.The s ubject is unable to withdraw any  of the f ollowing medicat ions listed in Table 7.a
48hours prior to the study .
7.The subject has a clinically significant abnormal baseline safet y laboratory  value.
8.The subject has preexist ing hepat ic disease that meets Child -
Pugh Class B (moderate; total 
score 7 to 9 points) or C (severe; total score 10 to 15 points), see Appendix E. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 31of 86
Protocol Incorporating Amendment No. 05 19 December 2018
9.Subjects without known preexist ing hepat ic disease who have 1 or more of the fo llowing:
AST or ALT >2 times the ULN.
Bilirubin >1.5 times the ULN unless due to Gilbert’s syndrome.
Internati onal normalized rati o (INR) >1.5 unless on anticoagulat ion therapy .
10.The subject has QTcF interval ≥460 msec or with other factors that increase the risk of QT 
prolongati on or arrhy thmic events at screening. Note: Subjects with bundle branch block and 
a pro longed QTc interval, or with QTcF between 450 and 460 msec, should be reviewed by 
the medical mo nitor for potenti al inclusi on. 
11.Subjects who have second or third degree atrioventricular (AV) block; AV disassociat ion; 
>5beats of non -sustained VT at a rate >120 bpm; ECG changes consistent with acute 
myocardial  ischemia or infarct ion.
12.The subject has a cardiac history  that includes condit ions requiring HR control (eg, atrial 
fibrillat ion, atri al flutter, ventri cular tachycardia, or other tachyarrhy thmias).
13.The subject has clinical evidence (including physical examinat ion, ECG, clinical laboratory  
value and review o f the medical history ) of significant cardiovascular, respiratory , moderate 
or severe renal insufficiency  (creat inine clearance ≤60 m L/min), hematol ogical, neurol ogical , 
psychiatric, or other disease that interferes with the object ives of the study.
14.If female, are pregnant or lactating or intending to beco me pregnant before participat ing in 
this study , during the study , and wi thin 4 to 5 days (5 half -lives) PLUS 30 days after last dose 
of the study  drug; or intending to donate ova during such time period.
15.If male, the subject intends to donate sperm during the course of this study  or for 4 to 5 days 
(5half-lives) PLUS 30 days thereafter.
16.The subject is considered by the invest igator to be an alcoho lic not in remissio n or known 
substance abuser; have a history  of alcohol  consumpt ion exceeding 2 standard drinks per day  
on average (1 glass is approximately  equivalent to: beer [354 mL/12 ounces], wine 
[118mL/4 ounces], or dist illed spirits [29.5 mL/1 ounce] per day ).
17.A subject, who in the determination o f the invest igator, possesses any condit ion that the 
investigator believes would put the subject at risk or would preclude the subject from 
successfully c ompleting all aspects of the study .
7.3 Excluded Medications
Subjects m ust be instructed not to take any  medicati ons including over -the-counter products, 
without fi rst consul ting wi th the investi gator. Use of excluded agents (prescript ion or 
nonprescript ion) is outline in Table 7.a.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 32of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Table 7.a Excluded Medications
Medication
Drugs known to alter GI transit including laxatives, 
magnesium or aluminum -containing antacids, 
prokinetics, erythromycin, narcotics, anticholinergics, 
tricyclic antidepressants.Monoamine oxidase inhibitors.
Selective serotonin reuptake inhibitors: escitalopram, 
citalopram, fluoxetine, sertraline, paroxetine, 
fluvoxamine, and newer antidepressants.Serotonin and norepinephrine reuptake inhibitors: 
venlafaxine, duloxetine, desvenlafaxine, milnacipran, 
levomilnacipran.
Analgesic drugs including opiates, nonsteroidal 
antiinflamatories, cy clooxygenase -2 inhibitors.Benzodiazepines.
Antidiabetes treatment with pramlintide or glucagon -
like peptide -1 receptor agonists.N-methy l-D-aspartate receptor antagonist. phencyclidine, 
ketamine, tiletamine, methoxetamine, dextromethorphan, 
pethidine, levorphanol, methadone, dextropropoxyphene, 
tramadol, ketobemidone.
Gamma -aminobutyric acidergic (GABAergic) agents: 
bicuculline, securinine, metrazol, flumazenil.5-HT agonist.
Note: Low stable doses of thyroid replacement, estrogen replacement, aspirin for cardioprotection, and birth control 
pills or depot injections; metformin, dipeptidyl peptidase -IV inhibitors, and insulin for diabetes are permissible.
7.4 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or w ithdrawal of the subject fro m the study  or study drug 
shoul d be recorded in the case report form eCRF using the following categories. For screen 
failure subjects, refer to Section 9.1.15 .
1.Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires 
early  terminat ion because continued participation imposes an unacceptable risk to the 
subject’s health or the subject is unwilling to continue bec ause of the PTE or AE.
2.Liver Funct ion Test (LFT) Abnormalit ies
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status , see Section 9.1.8 ), if the fo llowing ci rcumstances occur at any  time 
during study  drug treatm ent:
– Alanine aminotransferase (ALT) or aspartate ami notransferase (AST) >8 × ULN, or
–ALT or AST >5 × ULN and persists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × ULN or INR 
>1.5, or
–ALT or AST >3 × ULN with appearance of fat igue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 33of 86
Protocol Incorporating Amendment No. 05 19 December 2018
3.Significant protocol  deviat ion. The discovery  (postrandomizat ion) that the subject failed to 
meet protocol entry  criteria or di d not adhere to protocol requirements, and continued 
participat ion poses an unacceptable risk to the subject’s healt h.
4.Lost to follow -up. The subject did not return to the clinic and after 3 attempts to contact the 
subject were unsuccessful. Attempts to con tact the subject must be documented in the 
subject’s s ource docum ents. 
5.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from  the study . The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine t he underlying reason for the withdrawal 
and, where possible, the primary  underlying reason shoul d be recorded (i e, wi thdrawal  due to 
an AE should not be recorded in the “vo luntary withdrawal” category .
6.Study  terminat ion. The sponsor, IRB, or regulatory age ncy terminates the study .
7.Pregnancy. The subject is found to be pregnant .
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.10 .
8.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.5 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any  time during the study  
when the subject meets the study  terminati on cri teria described in Sect ion 7.4. In addit ion, a 
subject may discont inue his or her pa rticipat ion without giving a reason at any  time during the 
study . Shoul d a subject’s participat ion be discont inued, the primary criterion for terminat ion 
must be recorded by  the invest igator. In addit ion, efforts should be made to perform all 
procedures sc heduled for the Early Terminat ion Visi t. Discont inued or withdrawn subjects will 
notbe replaced.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 34of 86
Protocol Incorporating Amendment No. 05 19 December 2018
8.0 CLINICAL STUDY MATER IAL MANAGEMENT
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
In thi s protocol , the term  study  drug refers t o all or any  of the drugs defined below.
8.1.1.1 TAK-954
The drug product, TAK -954 Inject ion (Concentrate for Solut ion for Infusio n), consists of a clear 
colorless so lution of TAK -954 free base in clear Type I glass vials fitted with a rubber stopper 
and sealed wi th an al uminum  cap. The drug product i s formulated as 0.1 mg/mL o f TAK -954 
free base equivalent disso lved in water for inject ion, adj usted to pH 5.0 with hydrochloric acid 
and/or sodi um hydroxi de. Each gl ass vial  contains 5.5 m L of sterile TAK -954 sol utiondesigned 
to deliver no minally 5.0 mL of the so lution. The drug product solut ion is intended to be diluted 
to the required concentration with a diluent for IV infusio n. The placebo IV infusio n solution is 
the diluent only  and prepared in the same manner as the active. Please see the pharmacy manual 
for preparati on and administration instructions .
TAK -954 cartons and vials will be affixed with clinical labels that are in accordance with all 
regul atory  requi rements.
8.1.1.2 Ancillary Materials 
All ancillary supplies will be provi ded by eit her the site or Takeda, based upon availabilit y. If 
provi ded by Takeda, unused ancillary  supplies will be accounted for and disposed of as directed 
by Takeda or a Takeda designee.
8.1.2 Storage
The requi red storage condit ion for TAK -954 study drug is refrigeration between 2°C and 8°C. 
Study  drug m ust be kept in an appropriate, limited -access, secure place unt il it is used or returned 
to the sponsor or designee for destruction. Study  drug m ust be stored under the conditions 
specified on the label, and remain in the original container unt il dispensed. A daily temperature 
log of the drug storage area must be maintained every  working day .
8.1.3 Dose and Regimen
The subjects will be randomized to TAK -954 0. 1, 0.3, or 1 mg; or placebo and will receive 
TAK -954 or pl acebo as a 60 -minutes infusio n IV once a day  for 3 day s starting on Day  1. The 
number of act ive treatment arms decreased based upon the prespecified interim analysis. To 
maintain the blinding of the study  team , the specific treatment arm is not ident ified. This change 
was not necessitated by  safety  findings.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 35of 86
Protocol Incorporating Amendment No. 05 19 December 2018
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of study  drug, to or by  
a study  subject, at a dose above that which is assigned to that individual subject according to the 
study  protocol .
All cases of overdose (with or without associated AEs) will be documented o n an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs 
associ ated wi th an overdose will be documented on AE CRF( s) according to Section 10.0.
SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on10.2.2 .
In the event of drug overdose, the subject should be treated symptomat ically. 
8.2 Study Drug Assignment and Dispensing Procedures
Subjects will be assigned to receive their treatment according to t he rando mizat ion schedule 
allocated to the study  site.
8.3 Randomization Code Creation and Storage
Randomization personnel or the designee o f the sponsor will generate the randomizat ion 
table/schedule and will provide it to the site pharmacist prior to the sta rt of this study . All 
rando mizat ion informat ion will  be stored in a secured area, accessible only  by authori zed 
personnel.
8.4 Study Drug Blind Maintenance 
The study  drug blind is maintained through a randomizat ion schedule held by authorized persons 
only.
8.5 Unblinding Procedure 
The study  drug blind shall not be broken by  the investi gator unl ess inform ation concerning the 
study  drug i s necessary for the medical treatment of the subject. All study  assessments and 
causalit y assessment shoul d be performed, if poss ible, prior to unblinding. In the event of a 
medical emergency, if possible, the medical mo nitor should be contacted before the study  drug 
blind is broken to discuss the need for unblinding.
The sponsor must be notified as soon as possible if the study  drug blind is broken. The date, 
time, and reason the blind is broken must be recorded in the source documents and the same 
inform ation (except the time) must be recorded on the eCRF.
If any site personnel are unblinded, study  drug m ust be stopped immediately and the subject 
must be withdrawn fro m the study . 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 36of 86
Protocol Incorporating Amendment No. 05 19 December 2018
8.6 Accountability and Destruction of Sponsor- Supplied Drugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee or destroy ed locally.
The investigator or designee must ensure that the sponsor -supplied drug is used in accordance 
with the protocol  and is dispensed only to subjects enrolled in the study . To docum ent 
appropriate use of sponsor -supplied drug, the investigator or designee must maintain records of
all sponsor -supplied drug delivery  to the si te, si te inventory , dispensat ion and use by each 
subject, and return to the sponsor or designee or destroy ed locally .
The invest igator or designee must maintain 100% accountabilit y for all sponsor -supplied drugs
received, dispensed and remaining at the conclusio n of the study . For all  study  sites, the l ocal 
country  sponsor personnel or designee will provide appropriate documentation that must be 
completed for clinical study  drug accountabilit y, return and/or dest ruction.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified 
immediately .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 37of 86
Protocol Incorporating Amendment No. 05 19 December 2018
9.0 STUDY PLAN
9.1 Study Procedures
The fo llowing sect ions describe the study  procedures and data to be collected. For each 
procedure, subjects are to be a ssessed by  the same investi gator or si te personnel whenever 
possible. The Schedule of Study  Procedures i s located i n Appendix A.
9.1.1 Informed Consent Proced ure
The requi rements of the informed consent are described in Sect ion 15.2.
Inform ed consent m ust be obtained prior to the subject entering into the study , and before any 
protocol -directed procedures are performed.
A unique subject ident ificat ion number (subject number) will be assigned to each subject at the 
time that informed consent is obtained; this subject number will be used throughout the study .
9.1.2 Demographics, Medical History, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth, sex, ethnicit y, race as 
described by the subject, height, weight, and smoking status of the subject at Screening.
Medical history  to be obtained will include determining whether the subject has any  significant 
condi tions or di seases rel evant to the di sease under study  that resolved at or prior to signing of 
inform ed consent. Ongoing condit ions are considered concurrent medica l condi tions (see 
Secti on9.1.7 ).
Medicat ion history  informat ion to be obtained includes any medicat ion relevant to eligibilit y 
criteria and effica cy/safet y evaluat ion stopped at or within 48 hours prior to signing of informed 
consent.
9.1.3 Physical Examination Procedure
A baseline physical examinat ion (defined as the assessment prior to first dose of study  drug) will 
consist of the fo llowing body  systems : (1) ey es; (2) ears, nose, throat; (3) cardiovascular system; 
(4)
respi ratory  system; (5) GI sy stem; (6) dermatologic system; (7) extremit ies; 
(8)musculo skeletal  system; (9) nervous system looking for hy perreflexia, hypertonicit y and 
clonus; (10) lymph nodes; and (11) other. All subsequent physical examinat ions should assess 
clinically significant changes fro m the assessment prior to first dose examinat ion.
9.1.4 Weight, Height and BMI 
A subject should have weight and height measured while wearing indoor cloth ing and with shoes 
off. Height is recorded in cent imeters without decimal places. Weight is co llected in kilograms 
(kg) wi th 1decimal place. BMI should be derived as:
Metri c: BMI = wei ght (kg)/height (m)2
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 38of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Note that although height is reported in centimeters, the formula uses meters for height; meters 
can be determined fro m centimeters by dividing by 100. Thus, for example, if height=176 cm 
(1.76 meters) and weight=79.2 kg, then BMI=79.2/1.762=25.56818 kg/m2
The values should be reported to 1 decim al place by  rounding. Thus, in the above example BMI 
woul d be reported as 25.6 kg/m2. However, if the BMI is used as entry  criteria based on 
40kg/m2cut-off po int, then this determinat ion must be made after rounding. 
9.1.5 Vital Sign Procedure
Vital signs will include sitt ing/supine blood pressure (systolic and diastolic, resting more than 
5minutes), and pulse (beats per minute).
When vital signs are scheduled at the same time as PK blood draws, the PK blood draw will take 
priori ty and vi tal signs will  be obta ined within 0.5 hour before or after the scheduled blood draw.
9.1.6 Documentation of Concomitant Medications
Concomitant medicat ion is any drug given in addit ion to the study  drug. These may  be 
prescribed by  a physician or obtained by  the subject over the count er. Concomitant medicat ion is 
not provi ded by  the sponsor. At each study  visit, subjects will be asked whether they  have taken 
any medicat ion other than the study  drug (used from signing of informed consent through the 
end of the study ), and all medicat ionincluding vitamin supplements, over -the-coun ter 
medicat ions, and oral herbal preparations, must be recorded in the eCRF.
9.1.7 Documentation of Concurrent Medical Conditions
Concurrent medical condit ions are those significant ongoing condit ions or di seases that are 
present at signing of informed consent. This includes clinically significant laboratory , ECG, or 
physical examinat ion abnormalit ies noted at screening examination, according to the judgment of 
the invest igator. The condit ion (ie, diagnosis) should be described.
9.1.8 Procedures for Clinical Laboratory Samples
All samples will be co llected in accordance with acceptable laboratory  procedures. Details of 
these procedures and required safet y monitoring will be given in the laboratory  manual .
Table 9.alists the tests that will be obtained for each laboratory  specimen.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 39of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Table 9.a Clinical Laboratory Tests
Hemato logy Serum Chemistry Urinalysis
RBC
WBC with 
differentials
Hemoglobin
Hematocrit
PlateletsALT
AST
Albumin
Alkaline phosphatase
Total bilirubin
Total protein
Creatinine
Blood urea nitrogen
Creatine kinase
γ-glutamyl transferase (GGT)
Potassium
Sodium
Glucose
HbA1c (a)
TSH (a)pH
Specific gravity
Protein
Glucose
Blood
Nitrite
Microscopic analysis (RBC/high power field, WBC/high 
power field, epithelial cells, casts, etc.) to be performed if 
abnormal.
Other:
Serum Urine Coagulation
Hepatitis panel, including HBsAg 
and anti -HCVBeta hCG (female subjects only) INR
Female subjects only:
Beta human chorionic gonadotropin 
([hCG] for pregnancy)
Follicle -stimulating hormone
(FSH )
If menopause is suspected.
HbsAg=hepatitis B virus surface antigen, HCV=hepatitis C virus, RBC=red blood cell, WBC=white blood cell.
(a)HbA1c and TSH to be collected at Screening only.
The l ocal laboratory  will perform laboratory  tests for hem atology, serum  chemistri es, and 
urinalysis. The results of laboratory  tests will be returned to the investigator, who is responsible 
for reviewing and filing these results.
If subjects experience ALT or AST >3 ×ULN, follow -up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed wi thin a 
maximum o f 3 day s and preferably within 48- 72 hours after the abnormalit y was noted. (Refer to 
Secti on 7.4and Section 10.2.3 for the appropriate guidance on reporting abnormal LFTs.)
If ALT or AST remains elevated >3 ×ULN on these 2 consecut ive occasio ns the investigator 
must contact the medical mo nitor for consi derat ion of addit ional testing, cl ose m onitoring, 
possible discont inuat ion of study  drug, di scussio n of the relevant subject details and possible 
alternat ive etio logies. The abnorm ality should be recorded as an AE (please refer to 
Secti on10.2.3 ).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 40of 86
Protocol Incorporating Amendment No. 05 19 December 2018
9.1.9 Contraception and Pregnancy Avoidance Procedure
9.1.9.1 Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the study , and for 4 to 5 days 
(5half-lives) PLUS 30 days after last dose of study drug, nonsterilized** male subjects who are 
sexually  active wit h a female partner of childbearing potential* must use barrier contracept ion 
(eg,condom with or without spermicidal cream or jelly). In addition, they must be advised not to 
donate sperm during this period. Females o f childbearing potential who are partners of male 
subjects are also advised to use addit ional contraception as s hown in the list containing highly 
effect ive contraception below.
9.1.9.2 Female Subjects and Their Male Partners
Animal studies for TAK -954 have dem onstrated embry otoxi city and there i s a lack of  adequate 
reproducti ve toxi city data in humans; therefore, female su bjects shoul d be instructed to use
highly  effect ive methods of contraception.
From  signing of informed consent, throughout the duration of the study , and for 4 to 5 days 
(5half-lives) PLUS 30 days after last dose of study drug, female subjects of childbea ring 
potenti al* who are sexually act ive with a nonsterilized male partner** must use a highly 
effect ive methodof contracepti on (f rom the list below). 
Methods: 
Combined (estrogen and progestogen) hormonal contraception associated with inhibit ion of 
ovulation.
–Oral. 
–Intravaginal.
–Transdermal. 
Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation.
–Oral. 
–Injectable.
–Implantable.
IUD.
Bilateral tubal occlusio n.
In addit ion, they  must be advised not to donate ova during this period .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 41of 86
Protocol Incorporating Amendment No. 05 19 December 2018
9.1.9.3 Definitions and Procedures for Contraception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
*A wo man is considered a woman of childbearing potential (fertile) fo llowing menarche and 
until becoming post -menopausal unless permanently  sterile. Perm anent sterilizat ion methods 
include hysterectomy, and bilateral oophorectomy . A postmenopausal state is defined as no 
menses for 12 months wit hout an alternative medical cause. A high FSH level in the 
postmenopausal range (FSH >40 IU/L) may be used to confirm a postmenopausal state in 
younger wom en (eg, those < 45 y ears ol d) or women who are not using hormonal contraception 
or horm onal replacement therapy . However, in the absence of 12 months of amenorrh ea, a single 
FSH m easurement is insufficient.
**Sterilized males should be at least 1 y
ear postbilateral vasectomy and have confirmed that they  
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
The follow ing procedures apply for contraception and pregnancy avoidance.
1.Highly effect ive methods of contraception are defined as “those, alone or in co mbinat ion, 
that resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly 
and correctly). In this study , where medicat ions and devices containing hormones are 
included, the only  acceptable methods of contraception are: 
Nonhorm onal Methods: 
–IUD.
–Bilateral tubal occlusio n.
Horm onal Methods: Horm onal contracepti on m ay be suscept ible to interaction with the 
investigat ive co mpound and concomitant medicat ions, which may reduce the efficacy o f 
the contraception method (Evaluate on compound -by-compound and 
protocol -by-protocol  basis and obtain clinical pharmaco logy justificatio n).
–Combined (estrogen and progestogen) hormonal contraception associated with 
inhibit ion of ovulation initiated at least 3 months prior to the first dose of study  drug 
OR combined with a barrier method (male condom, female condo m or diaphragm) if 
for shor ter durati on unt il she has been on contraceptive for 3 months;
Oral.
Intravaginal (eg, ring).
Transdermal.
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation 
initiated at least 3 months prior to the first dose of study drug in combinat ion with a 
barrier m ethod (m ale condom , female condo m, or di aphragm );
Oral.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 42of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Injectable.
Implantable.
2.Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, post -ovulation methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of contraception.
3.Subjects will be provided with information on highly effect ive methods of contraception as 
part of the subject informed consent process and will be asked to sign a consent form stating 
that they  understand the requirements for avoidance of pregnancy, donation of ova, and 
sperm  donat ion during the course of the study .
4.During the course of the study , regular serum /urine hCG pregnancy  tests will be perform ed 
only for wom en of childbearing potential and all subjects (male and female) will receive 
continued guidance with respect to the avo idance of pregnancy and sperm don ation as part of 
the study  procedures. Such guidance should include a reminder of the following:
a)Contraceptive requirements of the study .
b)Reasons for use of barrier methods (ie, condom) in males with pregnant partners.
c)Assessment of subject compliance through questi ons such as:
i.Have you used the contraception consistent ly and correctly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cycles 
a pregnancy test must be performed if the answer is “yes”).
iv.Is there a chance you could be pregnant ?
5.In addit ion to a negative serum hCG pregnancy test at Screening, female subjects of 
childbearing potential must also have confirmed menses in the mo nth before first dosing (no 
delayed menses); a negat ive serum hCG pregnancy test prior to the first dose of study 
medicat ion (Day  1; if a negative serum hCG pregnancy test was obtained on Day  -1, then the 
serum  pregnancy  test on Day  1 can be discont inued); and a negat ive urine pregnancy test 
within 48 hours pri or to consuming a radiolabeled meal. A serum hCG test may subst itute for 
a urine pregnancy test as long as the timing of the test as required is appropriately 
maintained. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 43of 86
Protocol Incorporating Amendment No. 05 19 December 2018
9.1.9.4 General Guidance With Respect to the A voidance of Pregnancy
Such guidance should include a reminder of the fo llowing:
Contraceptive requirements of the study .
Reasons for use of barrier methods (ie, condom) in males with partners of childbearing potential.
Assessment of subject compliance thro ugh questions such as:
–Have you used the contraception consistent ly and correctly since the last visit ?
– H ave y ou forgotten to use contraception since the last visit ? 
–Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregn ancy test m ust be performed if the answer is “yes”)?
–Is there a chance you could be pregnant ?
9.1.10 Pregnancy
If any subject is found to be pregnant during the study , she shoul d be wi thdrawn and TAK -954 
shoul d be immediately discont inued. In addit ion, any  pregna ncies in the partner of a male subject 
during the study  or for 4 to 5 day s (5 half -lives) PLUS 30 days after the last dose, should also be 
recorded fo llowing authori zation from the subject’s partner.
If the pregnancy  occurs during administration of active study  drug, from  Day 1 up to 4 to 5 days 
(5half-lives) PLUS 30 days of the last dose of act ive study  drug, the pregnancy  should be 
reported immediately, using a pregnancy  notificat ion form, to the contact listed in Sect ion 1.0.
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to
receive unblinded treatment informat ion, the individual blind should be broken by the 
investigator. Subjects rando mized to placebo need not be fo llowed.
If the female subject and/or female partner of a male subject agrees to the primary care physician 
being informed, the invest igator should notify the primary care physician that the female 
subject/female partner of the subject was participating in a clinical study  at the time she became 
pregnant and provide details o f the study  drug the subject received (b linded or unblinded, as 
applicable).
All pregnancies, including female partners of male subjects, in subjects on active study  drug will  
be followed up to final outcome, using the pregnancy  form. Pregnancies will remain blinded to 
the study  team . The outcom e, including any premature terminat ion, must be reported to the 
sponsor. An evaluation after the birth of the child will also be conducted.
9.1.11 ECG Procedure
A standard 12- lead ECG will be recorded. The investigator (or a qualified observer at the study 
site) will interpret the ECG using 1 of the fo llowing categori es: wi thin norm al limi ts, abnormal  
but not clinically  significant, or abnormal and clinically sign ificant. 12 -lead ECG will be 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 44of 86
Protocol Incorporating Amendment No. 05 19 December 2018
perform ed on Days 1, 2, and 3 prior to each IV infusion; wit hin 30 minutes postinfusion and 
prior to di scharge; and at the Final Visit on Day 4 or Early  Terminat ion Visit. In addit ion, a 
12-lead ECG will be performed when needed, if a subject develops symptoms or clinical signs 
suggest ive of cardio vascular origin (eg, dizziness, lightheadedness, chest pain, chest heaviness, 
palpitations, shortness of breath, tachy cardi a).
The time that the ECG was performed will be recorded . The fo llowing parameters will be 
recorded on the eCRF fro m the subject’s ECG trace: heart rate, RR interval, PR interval , 
QT 
interval , QRS interval, and QT and QTcF . 
All participat ing subjects will have a 6 -hour Holter monitor placed at the Baseline Vis it. On 
Day 1, subjects will have continuous monitoring wit h a Hol ter m onitor whi ch will be placed 
prior to the first dose until the morning of Day  3. Interpretati on of  the Hol ter m onitor recording 
will be performed by  a May o cardi ologist.
9.1.12 Scintigraphy Proc edure
An adaptation of the May o Clinic’s established scint igraphic method will be used to measure GI 
transi t. A radi olabeled m eal of 99mTc (technet ium-99m)-sulfur collo id added to 2 scrambled eggs 
will then be eaten with 1 slice of who le wheat bread and 1 glass of skim milk. This meal 
facilitates measurement of gastric and small bowel transit. 111In (indium chloride isotope )-
absorbed on activated charcoal particles will be delivered to the colon by means of a 
methacrylate- coated, delayed -release capsule.
Atthe Baseline Visit ( between Days -14 and -1), subjects will ingest the radiolabeled 
standardized test meal fo llowed by  scans after ingesti on at 0, 1, 2, 3 and 4 hour timepoints. 
On Day  2, subjects will  ingest the radi olabeled (111In) charcoal capsule jus t prior to the 
60-minute infusio n of TAK -954. The radi olabeled breakfast for scint igraphic study  will be given 
at the end of the TAK -954 infusio n. Relat ive to the time of co mpletion of the breakfast meal 
ingestion, abdo minal images are obtained pre -meal, i mmediately fo llowing the radiolabeled 
meal, and every  30minutes fo llowing the m eal for the first 4 hours and then hourly  until 8 hours 
(5 and 9 hours post start of infusio n on Day  2), then at 24 and 48 hour timepoints post breakfast 
meal on Day  2 (1 hour and 25 hours post start of infusio n on Day  3). Foll owing the fi rst day  of 
study  drug administrati on on Day  1, subjects will return the next 2 day s (Days 2 and 3) for IV 
administration of study  medicati on. On Days 3 and 4, subjects will return in the mornin
g for the 
24-and 48 -hour abdominal images, respectively. The performance characterist ics of this test are 
summarized in Scint igraphy: Gastric Empt ying, Small Bowel, and Co lonic Transit SOPs by 
Enteri c Physi ology and Imaging Facilit y. 
All subjects on trea tment will consume the same test meal as above fo llowed by  standardized test 
meals at l unch and afternoon snack at 4 and 8 hours after the radio labeled meal, respect ively. 
Prior to the 4 -hour scan on Day 2, a standard meal (chicken, potato, pudding “Stan ghellini” 
meal), 550 kilocalorie (kcal ) will be ingested. Hourly  images will  be taken unt il 8 hours 
post-radio labeled meal, when the second standard roast beef sandwich “Greydanus” 750 kcal 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 45of 86
Protocol Incorporating Amendment No. 05 19 December 2018
snack is ingested 15 minutes prior to the scheduled 8 -hour scan. T he subject will leave the study  
center at the end of the afternoon. They  will be asked to return the fo llowing days fast ing 
(Day s3 and 4), for IV administration of study  medicat ion (Day  3 only) and the image at 24 
(Day 3) and 48 hours (Day  4) af ter the in gesti on of radi olabeled m eal on Day  2.
All efforts will be made to obtain the scint igraphy  scans at the exact nominal t ime relat ive to 
dosing. However, samples obtained wit hin 10 to 15 minutes of the no minal t ime from dosing 
will not be captured as a proto col deviat ion, as l ong as the exact time of dosing and time of scan 
is noted on eCRF.
9.1.13 Pharmacogenomic and Biomarker Sample Collection
9.1.13.1 Biomarker Sample Collection
Proper f T applicable Terms of Use
CCI
CCI
TAK -954
Study No. TAK -954-2003 Page 46of 86
Protocol Incorporating Amendment No. 05 19 December 2018
9.1.14 PK Sample Collection and Analysis
9.1.14.1 Collection of Plasma for PK Sampling
The subjects will have PK samples co llected as follows:
Days 1: prior to dosing (0 hour), 1 (end of infusio n), 2, and 4 hours after start of infusio n. 
Day 2: pri or to dosing (0 hour), 1 (end of infusio n), 2, 5, 7, and 9 hours after the start of the 
infusion. 
Day 3:prior to dosing (0 hour), 1 (end of infusio n), and 2 hours after start of infusion.
Day 4: 25 hours after the start of infusion on Day  3 (48 hours after the administration of the 
radiolabeled meal and capsule on Day  2, sam e time as the 48 -hour geometric center 
measurement).
PK samples co llected during the infusio n will  be drawn from  the opposi te arm  from where the 
infusio n is delivered. All efforts will be made to obtain the PK and PD samples at the exact 
nominal t ime relative to dosing. Howe ver, samples obtained within 10% of the no minal time 
Property of Takeda: For non-comme se
CCI
TAK -954
Study No. TAK -954-2003 Page 47of 86
Protocol Incorporating Amendment No. 05 19 December 2018
from dosing will not be captured as a protocol deviation, as long as the exact date and time o f 
dosing (start and ending of infusio n) and the sampling collect ion is noted on eCRF.
Primary specimen co llection parameters are provided in Table 9.b.
Table 9.b Primary Specimen Collections
Specimen NamePrimary 
Specimen Description of Intended Use Sample Collection
Plasma sample for TAK -954 PK Plasma Pharmacokinetic 
measurementsMandatory
If indicated, these collected samples may also be assayed for metabo lites and/or addit ional PD 
markers.
9.1.15 Documentation of Screen Failure
Invest igators must account for all subjects who sign informed consent.
If the subject is withdrawn at the Screening Visit, the invest igator should complete the eCRF.
The primary  reason for screen failure is recorded in the eCRF using the following categories:
PTE/AE.
Did not m eet incl usion criteria or di d meet exclusion criteria. <specify reason>
Significant protocol  deviat ion.
Lost to follow -up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other study -specific.
Other (specify reason).
Subject identificat ionnumbers assigned to subjects who fail screening should not be reused.
9.1.16 Documentation of Randomization
Only subjects who meet all of the inclusio n criteria and none of the exclusio n criteria are eligible 
for randomizat ion into the treatment phase.
Property of Takeda: For non-commercial use only and su plicable Terms of Use
CCI
CCI
CCI
TAK -954
Study No. TAK -954-2003 Page 48of 86
Protocol Incorporating Amendment No. 05 19 December 2018
If the su bject is found to be not eligible for randomizat ion, the invest igator should record the 
primary  reason for failure on the applicable eCRF.
On Day  1, if they fulfill eligibilit y criteria, the subjects will be randomized to TAK -954 (0.1, 0.3, 
or 1 m g) or pl acebo.
9.1.17 Blood Volume 
The m aximum  volume of  blood at any  single day  is approximately  50 mL, and the approximate 
total volume of blood for the study  is 250 m L.
Direct veni puncture i s the preferred method of blood collect ion. 
9.2 Monitoring Subject Treatment Comp liance
All supplies used to administer study  drug to the subject will be recorded on the eCRFs.
9.3 Schedule of Observations and Procedures
The schedule for all study -related procedures for all evaluat ions is shown in Appendix A. 
Assessments should be co mpleted at the designated visit/time po int(s).
9.4 Biological Sample Retention and Destruction
In thi s study , blood, and bl ood derived samples for bio marker measurement will be collected as 
described in Section 6.1. Any leftover bio marker samples if not utilized will be preserved and 
retained at sponsor selected for long term storage facilit y for up to 15 y ears fro m the end of 
study . After that time, the samples will be destroy ed.
The pharmacogeno mic (PGx) samples will be init ially stored at a vendor/com parable lab, under 
contract to Takeda, with validated procedures in place, and then preserved and retained at a 
sponsor -selected l ong-term storage facilit y, for up to but not l onger than 15 years, from the end 
of the study  when the study  report i s signed, o r if less, the m aximum  period permi tted under 
applicable law or until consent is wit hdrawn . 
The sponsor and vendors working wit h the sponsor will have access to the samples collected and 
any test results. All samples collected during the trial will be sto red securely  with limited access 
and the sponsor will require anyo ne who works with the samples to agree to hold the research 
inform ation and any results in confidence.
The sample will be labeled with a unique sample ident ifier as in the main trial but usi ng a code 
that is different from the code attached to the healt h informat ion and other clinical test results 
collected in the trial. The sample and data are linked to personal healt h information wit h code 
numbers; the samples are stripped of all personal i dentifying informat ion but a key  linking the 
samples to clinical analysis data exists. This link means that the subject may be ident ified but 
only indirect ly. The sample ident ifier will be kept secure by or on behalf of the sponsor.
Subjects who consented and provided a PGx sample for DNA analysis can wit hdraw their 
consent at any  time and request disposal of a stored sample. Any remaining sample that can be 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 49of 86
Protocol Incorporating Amendment No. 05 19 December 2018
ident ified as coming fro m the subject will be destroy ed. The tri al doctor and sponsor m ay 
continue t o use and distribute any  informat ion and test results gathered before the request to 
withdraw.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 50of 86
Protocol Incorporating Amendment No. 05 19 December 2018
10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS
10.1 Definitions
10.1.1 PTEs
A PTE i s defined as any  untoward m edical  occurrence in a clinical invest igation subject who has 
signed in formed consent to participate in a study  but pri or to administration of any study  drug; i t 
does not necessarily  have to have a causal relat ionship wit h study  parti cipat ion.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical invest igationsubject 
administered a drug; it does not necessarily have to have a causal relat ionship with this 
treatm ent.
An AE can therefore be any unfavorable and unint ended sign (eg, a clinically significant 
abnorm al laboratory  value), symptom, or disease temporall y associated wi th the use of a drug 
whether or not it is considered related to the drug.
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre- exist ing condit ion. (Interm ittent 
events for pre -exist ing condit ions or underlying disease should not be considered PTEs or AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discont inuat ion or a change in dose of study  drug or a concomitan t medicat ion.
Be considered unfavorable by the invest igator for any reason.
PTEs/AEs caused by a study  procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:
Each event should be recorded to represent a s ingle diagnosis. Accompanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as a PTE(s) or as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG findings are only  considered to be PTEs or AEs if they are 
judged to be clinically  significant (i e, if som e act ion or intervent ion is required or if the 
investigator judges the change t o be bey ond the range of normal physio logic fluctuati on). A 
laboratory  or ECG retest and/or continued monitoring of an abnormal value or finding is not 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 51of 86
Protocol Incorporating Amendment No. 05 19 December 2018
considered an intervention. In addit ion, repeated or additional noninvasive testing for 
verification, ev aluat ion or monitoring o f an abnormalit y is not consi dered an intervent ion.
If abnorm al laboratory  values or ECG findings are the result of pathology  for which there is an 
overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only sh ould be reported 
appropriately  as a PTE or as an AE.
Pre-exist ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as PTEs or AEs. Baseline 
evaluations (eg, l aboratory  tests, ECG, X -rays etc.) should NOT be recorded as PTEs unless 
related to study  procedures. However, if the subject experiences a worsening or complication of 
such a concurrent medical condit ion, the worsening or complicat ion should be recorded 
appropriately  as a PTE (worsening or complicat ion occurs before start of study  drug) or an AE 
(worsening or complicat ion occurs after start of study  drug). Invest igators should ensure that the 
event term recorded captures the change in the con dition (eg, “worsening o f…”).
If a subject has a pre -exist ing episodic concurrent medical condit ion (eg, asthma, epilepsy) any 
occurrence of an episode should only be captured as a PTE/AE if the condit ion beco mes more 
frequent, serious or severe in nature. I Investigators should ensure that the AE term recorded 
captures the change in the condit ion from Baseline (eg “worsening of…”).
If a subject has a degenerat ive concurrent medical condit ion (eg, cataracts, rheumatoid arthrit is), 
worsening of the condit ionshoul d only  be recorded as a PTE/AE if occurring to a greater extent 
to that which would be expected. Investigators should ensure that the AE term recorded captures 
the change in the condit ion (eg, “worsening of…”).
Worsening of PTEs or AEs:
If the subjec t experiences a worsening or complication of a PTE after the start of study  drug, the 
worsening or complicat ion shoul d be recorded as an AE. Invest igators should ensure that the AE 
term recorded captures the change in the PTE (eg, “worsening o f…”).
If the subject experiences a worsening or complication of an AE after any  change in study  drug, 
the worsening or complication should be recorded as a new AE. Investigators should ensure that 
the AE term recorded captures the change in the condit ion (eg, “worsenin g of…”).
Changes in intensit y of AEs /serious PTEs:
If the subject experiences changes in intensit y of an AE/seri ous PTE, the event should be 
captured once with the maximum intensit y recorded.
Prepl anned procedures (surgeries or intervent ions):
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of informed 
consent are not considered PTEs or AEs. However, if a preplanned procedure is performed early 
(eg, as an emergency) due to a worsening of the pre- exist ing condit ion, the w orsening of the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 52of 86
Protocol Incorporating Amendment No. 05 19 December 2018
condi tion shoul d be recorded as a PTE or an AE. Complicat ions result ing from any planned 
surgery  shoul d be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical co ndition 
shoul d not be recorded as PTEs or AEs, but should be documented in the subject’s source 
docum ents. Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):
Insufficient clinical response, efficacy, or pharmacologic act ion, should NOT be recorded as an 
AE. The invest igator must make the dist inction between exacerbation of pre -exist ing illness and 
lack of therapeut ic efficacy.
Overdose:
Cases of overdose with any  medicati on wi thout manifested side effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any manifested 
side effects will  be considered PTEs or AEs and will be recorded on the AE page of the eCRF.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term  “life threatening” refers to an event in which the subject was at risk of death at 
the time o f the event; it does not refer to an event that hypothetically  migh t have caused 
death if it were more severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes any eve nt or synonym described in the Takeda Medically Significant AE List 
(Table 10.a).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 53of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Table 10.a Takeda Medically Signif icant AE List 
Term
Acute respiratory failure/acute respiratory distress 
syndromeHepatic necrosis
Torsade de pointes / ventricular fibrillation / ventricular 
tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hypertension Acute renal failure
Convulsive seizure Pulmonary hypertension
Agranulocytosis Pulmonary fibrosis
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens -Johnson syndrome Confirmed or suspected transmission of infectious agent by 
a medicinal product
Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
Note: Terms identified on the Medically Significant AE List represent the broad medical concepts to be considered 
as “Impo rtant Medical Events” satisfying SAE reporting requirements. 
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and 
shoul d be reported and followed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.5 Management of Specific AEs
10.1.5.1 Cardiovascular Disorders
Cardi ovascular events:
Tegaserod, a nonselect ive 5 -HT 4agonist, was withdrawn fro m the market in 2007 based on 
pooled clinical tri al resul ts that suggested increased r isk o f cardi ovascular i schemic events. 
Alternat ively, TAK -954, highly  select ive 5 -HT 4agonist, did not demonstrate significant AEs 
related to cardi ovascular events in studies to date. In TAK -954 clinical  studi es, 1 subject 
received TAK -954 0.5 m g IV in the intensive care unit (ICU) fo llowing an emergency 
evacuat ion of a spontaneous posterior fossa intraparenchymal hemorrhage. This pat ient died due 
to her underlying admitting diagnosis. 
The m edical  monitor shoul d be contacted within 24 hours if a subject de velops cardiovascular 
events that include ischemic heart disease, cerebrovascular accident (eg, transient ischemic 
attack and stroke), venous or arterial thromboembolic events, and heart failure. 
QT Prolongation
Cisapride, a nonselect ive 5 -HT 4agonist and a potent human ether -à
-go-go–related gene blocker, 
was wi thdrawn from  the m arket due to the risk of prolonged QT interval and sudden death. 
In TAK -954 clinical studies, only 1 subject in Study  0082 had QTcF over 450 msec. This subject 
receive d TAK -954 0.5 m g IV was in the ICU fo llowing an emergency evacuation o f a 
spontaneous posterior fossa intraparenchymal hemorrhage. She had medical history o f atrial 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 54of 86
Protocol Incorporating Amendment No. 05 19 December 2018
fibrillat ion on warfarin, mitral valve replacement, and biventricular pacemaker, and on 
Screening, her QTcF was 461 msec. She had a maximum QTcF of 496 msec on Day  1 and she 
was not treated for this finding.
If a subject develops QT prolongation (QTcF) longer than 480 msec, study drug should be 
discontinued, levels of electroly tes (potassi um, ca lcium, and magnesium) should be checked and 
supplementati on given to correct any  values outsi de the norm al range, and concomitant therapies 
shoul d be reviewed and adjusted as appropriate for medicat ions with known QT prolonging 
effects. In addit ion, the m edical  monitor shoul d be contacted within 24 hours. Heart -rate 
corrected QT interval will be calculated using Fredericia’s formula (QTcF=QT/RR1/3). 
AV Dissociation/Heart Block
In Study  0061, 2 subj ects receiving TAK -954 10 mg orally  devel oped intermi ttent mild AEs o f 
AV dissociat ion. The finding reso lved without treatment. 
If subjects develop new onset first degree heart block, medical mo nitor will need to be contacted 
to discuss within 24 hours. Treatment with study  drug should be discont inued wit h the 
occurrence of any second or third degree heart block and the medical mo nitor shoul d be 
contacted within 24 hours.
Treatments with study  drug m ay be cont inued in second degree heart block Mobitz I 
(Wenckebach) after medical mo nitor revi ew.
Supraventricular Ta chycardia (SVT)
In Study  0061, there was a trend toward lower blood pressure and elevated HR in the standing 
position for TAK -954 subjects, but no dose response was apparent. One subject (Study 0095, 
TAK -954 0.5 m g dose) had the AE of postural tachycardia reported on Day  1, wi th HR values in 
the standing posit ion ranging from 100 to 116 bpm fro m 1 to 4 hours postdose. No other subject 
had HR values that were reported as AEs.
Treatment should be discont inued if a subject develops SVT at rest irrespect ive of the 
seriousness and the medical mo nitor shoul d be contacted wi thin 24 hours.
Hypotension
Asymptomat ic increases in both supine and standing HR were observed at all doses of TAK -954, 
and mean changes in supine and standing blood pressure were variable with no discernible 
pattern across the dose ranges. The dose escalat ion in the single ascending dose study  was 
stopped at 20 mg, according to the protocol -specified stopping rules, because of the occurrence 
of 2 AEs of m oderate orthostati c hypotensio n.
If subj ects devel op si gnificant hypotensio n, treatment wi th study  drug shoul d be perm anently 
discontinued.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 55of 86
Protocol Incorporating Amendment No. 05 19 December 2018
10.1.5.2 Serotonin Syndrome
Serotonin syndro me, a potentially life threatening adverse drug reaction, may result fro m drugs 
that increase the serotonergic act ivity in the central nervous system. The most commo nly 
implicated classes of drugs are select ive serotonin reuptake inhibitors. The clinical features may 
include agitat ion, confusio n, diarrhea, hyperthermia, tachycardia, hypertensio n, mydriasis, 
hypertoni city, and hyperreflexia.
If a subject develops any o f the following clinical features (Hunter’s criteria):
Spontaneous clonus.
Inducible clonus PLUS agitation or diaphoresis.
Ocul ar clonus PLUS agitation or diaphoresis.
Trem or PLUS hy perreflexia.
Hypertoni a PLUS t emperature above 38ºC PLUS ocular clonus or inducible clo nus.
Discontinue treatm ent wi th study  drug. In addi tion, revi ew the subject medications and 
discontinue any medicat ion(s) that may  be associ ated wi th serotonin syndro me. Suspected 
serotonin syndro me shoul d be reported to the sponsor as an SAE with 24 hours.
Shoul d any of these events occur in a subject, study  drug shoul d be di scontinued.
10.1.5.3 AESI
An AE of Special Interest (serious or nonserious) is 1 of scient ific and medical concern specific 
to the compo und or program, for which ongoing monitoring and rapid co mmunicat ion by the 
investigator to Takeda may  be appropri ate. If there are any  significant cardiovascular events, 
please contact the m edical m onitor to di scuss managem ent of  these events.
10.1.6 Intensity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The event is transient and easily tolerated by the subject.
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 56of 86
Protocol Incorporating Amendment No. 05 19 December 2018
10.1.7 Causality of AEs
The rel ationship of each AE to study  drug(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable te mporal sequence from administration of a drug (including 
the course after withdrawal of the drug), or for which possible involvement of the drug cannot 
be ruled out, although factors other than the drug, such as underlying diseases, complications, 
concomit ant medications and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug 
and/o r that can reasonably be explained by other factors, such as underlying diseases,
complications, concomitant medications and concurrent treatments.
10.1.8 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all PTEs and AEs.
The rel ationship should be assessed as Related if the invest igator considers that there is 
reasonable possibilit y that an event i s due to a study  procedure. Otherwise, the relat ionship 
shoul d be assessed as Not Related. 
10.1.9 Start Date
The start date of the AE /PTE is the date that the first signs/symptoms were noted by  the subject 
and/or invest igator.
10.1.10 Stop Date 
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but 
with sequelae or the subject died.
10.1.11 Frequency 
Episodi c AEs/PTE (eg, vomit ing) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.12 Action Concerning Study Drug 
Drug withdrawn –a study  drug i s stopped due to the particular AE.
Dose not changed – the particular AE did not require stopping a study drug.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a study  drug was stopped for a reason other than the particular AE eg, the study  
has bee n terminated, the subject died, dosing with study  drug was al ready stopped before the 
onset of the AE.
Dose reduced –the dose was reduced due to the particular AE.
Dose increased –the dose was increased due to the particular AE.
Dose interrupted –the dose was interrupted due to the particular AE.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 57of 86
Protocol Incorporating Amendment No. 05 19 December 2018
10.1.13 Outcome
Recovered/reso lved – Subject returned to first assessment status with respect to the AE/PTE.
Recovering/resolving –the intensit y is lowered by  1 or m ore stages: the diagnosis or 
signs/symptom s has almost di sappeared; the abnormal laboratory  value improved, but has not 
returned to the normal range or to baseline; the subject died from a cause other than the 
particular AE/PTE with the condit ion rem aining “recovering/reso lving”.
Not recovered/not resol ved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/ symptom s or l aboratory  value on the l ast day  of the observed 
study  period has got worse than when it started; is an irreversible congenital anomaly; the su bject 
died from another cause with the particular AE/PTE state remaining “Not recovered/not 
resolved”.
Reso lved with sequelae –the subject recovered from an acute AE/PTE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascul ar acci dent but wi th som e 
persisting paresis.
Fatal  –the AEs/PTEs which are considered as the cause of death. 
Unknown –the course of the AE/PTE cannot be followed up due to hospital change or residence 
change at the end of the subject’s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 PTE and AE Collection Period
Collect ion of PTEs will co mmence from the time the subject signs the informed consent to 
participate in the study  and cont inue until the subject is first administered study drug (Day  1) or 
until screen failure. For subjects who discont inue prior to study drug administration, PTEs are 
collected unt il the subject discont inues study  parti cipat ion.
Collect ion of AEs will co mmence fro m the time that the subject is first administe red study  drug 
Day 1). Routine collection of AEs will cont inue until the Follow -up Visi t.
10.2.1.2 PTE and AE Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeli ng since y our l ast visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing a 
serious PTE m ust be m onitored until  the symptoms subside and any clinically  relevant changes 
in laboratory  values have re turned to Baseline or there is a satisfactory  explanat ion for the 
change. Non -serious PTEs, related or unrelated to the study procedure, need not to be fo llowed-
up for the purposes of the protocol.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 58of 86
Protocol Incorporating Amendment No. 05 19 December 2018
All subjects experiencing AEs, whether considered associat ed with the use of the study  drug or 
not, m ust be m onitored until  the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to baseline or until there is a sat isfactory  explanat ion for the 
changes observed. All PTEs and AE s will be documented in the PTE/AE page of the eCRF, 
whether or not the invest igator concludes that the event is related to the drug treatment. The 
following informat ion will be documented for each event:
1.Event term .
2.Start and stop date.
3.Frequency.
4.Intensi ty.
5.Invest igator’s opinio n of the causal relationship between the event and administration of 
study  drug(s) (rel ated or not rel ated) (not com pleted for PTEs).
6.Invest igator’s opinio n of the causal relationship to study  procedure(s), including the details 
ofthe suspected procedure.
7.Action concerning study  drug (not applicable for PTEs).
8.Outcom e of event.
9.Seriousness.
10.2.1.3 AEs of Special Interest
AEs of special interest have to be recorded as AEs in the eCRF. An evaluation form alo ng with 
all other required docume ntation m ust be submitted to the sponsor.
An AE of special interest (serious or non -serious) is 1 of scient ific and medical concern specific 
to the compound or program for which ongo ing monitoring and rapid co mmunicat ion by the 
investigator to Takeda may  be appropri ate. Such events m ay requi re further investi gation in 
order to characterize and understand and would be described in protocols and instructions 
provi ded for investigators as to how and when they  should be reported to Takeda.
10.2.2 Collection and Report ing of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 1.1.
The invest igator should submit the original copy of the SAE form to the sponsor.
Any SAE spontaneously  reported to the investigator following the AE collect ion peri od shoul d 
be reported to the sponsor if considered related to study  parti cipat ion.
Reporting of Serious PTEs will fo llow the procedure described for SAEs.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 59of 86
Protocol Incorporating Amendment No. 05 19 December 2018
10.2.3 Reporting of Abnormal LFTs 
If a subject is noted to have ALT or AST elevated >3 ×ULN on 2 consecut ive occasions, the 
abnorm ality shoul d be recorded as an AE. In addition, an LFT Increases eCRF must be 
completed provi ding addi tional information on relevant recent history , risk factors, clinical signs 
and symptoms and results of any  addi tional diagnosti c tests perform ed.
If a subj ect is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on 10.2.2 . The investigator must con tact the m edical m onitor for discussi on of the 
relevant subject details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute live r disease or medical  history /concurrent m edical  condi tions. Fo llow-up laboratory  
tests as described in Sect ion 9.1.8 must also be performed. In addi tion, an LFT Increases eCRF 
must be completed and transmitted with the Takeda SAE form (as per Section
 10.2.2 ).
10.3 Follow -up of SAEs
If informat ion not available at the time of the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospi tal notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or permanent outcome of the event. The 
timelines and procedure for follow -up reports are the same as those for the init ial report.
10.3.1 Safety Reporting to Investigators, IRBs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, including invest igators and 
IRBs. Relat ive to the first awareness of the event by/or further provision to the sponsor or 
sponsor’s designee, SUSARs will be submitted to the regulatory  authori ties as expedi ted report 
within 7 days for fatal and life -threatening events and 15 days for other serious events, unless 
otherwi se requi red by  national regulat ions. The sponsor will also prepare an expedited report for 
other safet y issues where these might materially  alter the current be nefit-risk assessment of a 
study  drug/sponsor supplied drug or that would be sufficient to consider changes in the study  
drug/sponsor supplied drug administration or in the overall conduct of the study . The study  site 
also will forward a copy  of all expedi ted reports to his or her IRB .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 60of 86
Protocol Incorporating Amendment No. 05 19 December 2018
11.0 STUDY- SPECIFIC COMMITTEES
No steering committee, data safety  monitoring commi ttee, or clinical endpoint committee will be 
used in this study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 61of 86
Protocol Incorporating Amendment No. 05 19 December 2018
12.0 DATA HANDLING AND RE CORDKEEPING
The full details o f procedures for data handling wi ll be docum ented in the Data Management 
Plan. AEs, PTEs, medical history , and concurrent medical condit ions will be coded using the 
Medical Dict ionary for Regulatory  Activities (MedDRA). Drugs will be coded using the World 
Health Organizat ion (WHO) Drug Di ctionary.
12.1 CRFs (Electronic and Paper)
Com pleted eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply study  sites wi th access to eCRFs. The sponsor will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data are transcribed direct ly onto eCRFs.
After complet ion ofthe entry  process, com puter l ogic checks will be run to identify items, such 
as inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site .
Correcti ons to eCRFs arerecorded in an audit trail that captures the old information, the new 
inform ation, identificat ion of the person making the correction, the date the correction was made, 
and the reason for change. Reasons for significant corrections should addit ionally be i ncluded. 
The principal invest igator must review the eCRFs for completeness and accuracy and must 
e-sign the appropri ate eCRFs as indicated. Furthermore, the invest igator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of the study  database, any  change of, m odificati on of  or addi tion to the data on the 
eCRFs shoul d be m ade by  the invest igator with use of change and modificat ion records of the 
eCRFs . The principal invest igator must review the data change for completeness and accuracy , 
and must sign, or sign and seal, and date.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by the sponsor or its designee. The sponsor or its designee will be pe rmitted to review the 
subject’s medical and hospital records pertinent to the study  to ensure accuracy  of the eCRFs. 
The completed eCRFs are the sole property  of the sponsor and should not be made available in 
any form  to thi rd parti es, except for authoriz ed representatives of appropriate governmental 
healt h or regul atory  authori ties, wi thout wri tten permissio n of the sponsor. 
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and de tailed records of drug disposit ion to 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 62of 86
Protocol Incorporating Amendment No. 05 19 December 2018
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the origin al in the subject’s chart to ensure long term legibilit y. Furtherm ore, 
International Conference on Harmonisation E6 Section 4.9.5 requires the invest igator to retain 
essent ial docum ents specified in International Conference on Harmonisat ion (ICH) E6 
(Secti on8) until at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is not approved, until at least 2 years after 
the invest igation is discontinued and regulatory authorit ies are notified. In addit ion, ICH E6 
Secti on4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulatory  requi rements or for a time specified in the study  site agreem ent between 
the invest igator and sp onsor.
Refer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of 
any such documents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 63of 86
Protocol Incorporating Amendment No. 05 19 December 2018
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized prior to unblinding of subject’s 
treatm ent assi gnment. Thi s docum ent will provide further details regarding the definit ion of 
analysis variables and analysis methodology  to address all study  object ives.
13.1.1 Analysis Sets
Full Analysis Set: The full analysis set (FAS) will include all subjects randomized. Subjects in 
this set will  be analyzed according to the original rando mizat ion. This will be the main analysis 
set for efficacy  analyse s.
Per Protocol Set: The per protocol set (PPS) analysis set is a subset of the FAS. The PPS
consists of all subjects who do not vio late the terms of the protocol in a way that would 
significant ly impact the efficacy assessment. All decisio ns to exclude su bjects fromthe PPS
dataset will be made prior to the unblinding of the study and subject to clinical review. This 
analysis set will be for efficacy analyses only and can be considered as a sensit ivity analysis in 
support of the primary  analysis based on t he FAS.
Safety Set: The safety  set (SAF) will include all subjects who have received at least 1 dose of 
study  drug. Subj ects in this set will be analyzed according to the treatment they  actually 
received. This analysis set will be used for safety  analyses only.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographic and baseline characterist ics will be summarized by each treatment group and 
overall. Summary statist ics (N, m ean, SD, m edian, minimum, and maximum) will be generated 
for continuo us variables (eg, age and weight) and the number and percentage of subjects within 
each category  will be presented for categorical variables (eg, sex, ethnicit y, and race). Individual 
subject demographic and baseline characterist ics data will be listed.
13.1.3 Pharmacokinetic Analysis
PK parameters will be determined fro m the concentration -time data for all evaluable subjects 
using non -compartmental analysis. Actual sampling times, rather than scheduled sampling times, 
will be used in all PK computations invo lving sampling times for plasma PK parameters. 
For TAK -954, the following PK parameters including, but not limited to, will be calculated as 
appropriate:
Day 1: AUC τ, Cmax.
Day 2: AUC τ, Cmax, Ctrough.
Day 3: AUC τ, Cmax, Ctrough.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 64of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Addit ional PK parameters may  becalculated as appropriate. More detailed informat ion will be 
given in the clinical pharmaco logy analysis plan.
13.1.4 PD Analysis
The PD effect of TAK -954 will be assessed using a number of scint igraphic parameters.
Primary PD endpo int
The primary  PD endpoint wi ll be the T 1/2of gastri c em ptying of so lids. Geometric mean o f 
counts in anterior and posterior gastric regio ns of interest will be used to estimate by  power 
exponent ial analysis, the proportionate empt ying over time of counts fro m 99mTc solids and 111In 
from the stom ach. Gastri c empt ying from the power exponential analysis for the post inject ion 
period will be calculated and compared for the different treatments. The primary endpo int will be 
analyzed using analysis of covariance (ANCOVA) methods. The cova riates considered for 
inclusio n in the analyses will be gastroparesis ty pe (di abetic or idiopathic), age, gender, BMI, 
and the baseline measurement of gastric emptying T 1/2. Dunnett’s test will be used to compare 
each treatment arm to placebo. Multiplicit yadjusted and unadjusted 95% 2- sided CIs will be 
presented.
TheT 1/2 of gastric em ptying of so lids will be est imated by  the linear interpolat ion using the slope 
of the 2 data points before and after 50% has empt ied fro m the stom ach. If l ess than 50% em pty 
at 4 hours, the 3 data points at 180, 210, and 240 minutes will be used to project the time the T 1/2 
value.
Secondary  PD endpo ints
The secondary  PD endpoints will be:
Colonic geom etric center at 4, 24, and 48 hours after the radiolabeled meal.
Colonic filli ng at 6 hours (m easure of small bowel transit time) after the radio labeled meal.
T1/2 of ascending colonempt ying.
Colonic geom etric center at 4, 24, and 48 hours post meal will be est imated using geometric 
mean of counts in ascending, transverse, descendi ng and rectosigmo id co lon and stool (weighted 
by factors of 1 to 5, respectively ). The geometri c center is the weighted average of counts in the 
different colonic regions: ascending (AC), transverse (TC), descending (DC), rectosigmo id (RS), 
and stool . At a ny time, the portion of co lonic counts in each colonic regio n is multiplied by its 
weighting factors as fo llows: 
(%AC x 1 + %TC x 2 + %DC x 3 + %RS x 4 + %stool x 5)/100 = geometric center
Thus, a high geometric center implies faster colonic transit. A geometric center of 1 implies that 
all isotope is in the ascending co lon, and a geometric center of 5 implies that all isotope is in the 
stool . 
Colonic filling at 6 hours post meal will be es timated by  determining the am ount of i dentified 
99mTc -labeled so lid meal wit hin the colon at 6 hours with the value corrected for downscatter of 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 65of 86
Protocol Incorporating Amendment No. 05 19 December 2018
radioactivi ty from the 111Indium chloride isotope located within the same area appearing within 
the technet iumwindow of analysis.
T1/2of ascending colon empt ying will be estimated by power exponent ial analysis of the 
proporti onate em ptying over time of counts from the co lon. The primary data for this analysis 
will be the proportion of decay  and depth -corrected c ounts i n the ascending co lon on the hourly 
scans on the first day  of transi t measurement and the 24 hour data. The T 1/2of ascending co lon 
emptying is also estimated by plotting the act ivity-time curve for percent residing in the 
ascending colon; linear in terpol ation is used to connect points.
The secondary  endpoints will also be assessed using an ANCOVA model. The covariates 
considered for inclusio n in the analyses will be gastroparesis t ype (diabet ic or idiopathic), age, 
gender, BMI, and the baseline meas urement of the respective endpo int. The data may be 
transformed to correct for non -norm ality in the distributions of measured variables. If necessary , 
non-parametri c ANCOVA will be used.
13.1.5 Biomarkers
Descript ive statistics, graphical methods, and statistical modeling as appropriate will be used to 
explore the relat ionship between baseline levels/response and the levels o f various bio markers. 
13.1.6 Safety Analysis
AEs will be summarized using the safet y analysis set. No statist ical test ing or inferent ial 
statist icswill be generated. All AEs will be coded using MedDRA. Data will be summarized 
using preferred term and primary  system  organ class.
Vital signs, ECGs, and laboratory  param eters will  also be tabul ated.
13.1.7 Other Analyses
Patient Reported Outcomes:
Inform ation on the gl obal score using the GCSI, as well as bowel mo vement frequency per day  
and average stool consistency  on the Bri stol stool  form scale, will be tabulated and analyzed 
respectively .
13.2 Interim Analysis and Criteria for Early Termination
An interim analy sis was conducted when approximately half of the subjects have completed the 
study . Efficacy  and safet y data was reviewed to determine if the study  shoul d be m odified based 
on the interim analysis results. 
An execut ive co mmit tee wi thin Takeda co mposed of a senior clinician, a senior statist ician, a 
senior clinical  pharmacol ogist, and a senior pharmacovigilance scient ist not invo lved in the study  
have reviewed the interim analysis results and made recommendat ions for changes to the study . 
All members of the study  team  and the invest igative team will remain blinded to treatment arm 
assignment and treatment arm results until the complet ion of the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 66of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Based upon the results of the preplanned interim analysis, 1 of the TAK -954 doses was dropped. 
The specific dose dropped i s not specified in order to maintain the blind of the study  team . The 
sample size for the remaining treatment arms will not change.
13.3 Determination of Sample Size
Table 13.a below summarizes data for the primary response measures and uses the percent 
coefficient of variat ion, (%CV) to estimate the effect size detectable wit h 80% power based on a 
2sample z -test (i e, assuming the variat ion val ues are known) at a 2 -sided alpha l evel of 0.05. 
The effect size is the difference in group means as a percentage of the overall mean for each 
response and assumes 12 subjects per group. Based on data acquired using the same methods in 
the laboratory , the sample size of 12 subjects per group provides 80% power to detect 
approximately  30% changes in the primary endpoints of the study : gastric em ptying, and overall 
colonic transi t. Thi s magni tude of  change is considered clinically  significant. The ANCOVA 
shou ld provide 80% power to detect similar (pairwise) differences using a pooled est imate of 
variat ion across all 3 groups and potentially  even smaller effect sizes by adjust ing for important 
covari ates. The data from the scint igraphic transit studies are unpu
blished but based on the same 
methods proposed for this study .
Table 13.a Summary of Detectable Effect Sizes for PD Endpoints
Assuming n=12/Group in Each of the Dose Groups
Response Type Mean SD %CV Effect Size (%) †
Gastric emptying of solids T 1/2min (n=319) 122 29.8 24.5 34.2
Colonic filling at 6 h, % (n=63) 44 29 66 79
GC at 24 h (n=220) 2.4 0.9 36 52
Ascending colon T 1/2h (n=50) 15.0 8.0 53 63
GC= geometric center, h=hour, min=minute.
†Detectable with 80% power, =0.05.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 67of 86
Protocol Incorporating Amendment No. 05 19 December 2018
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator guarantees access to source documents by the sponsor or its designee (contract 
research organizat ion) and by  the IRB.
All aspects of the study  and i ts docum entati on will be subject to review by the sponsor or 
sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
Invest igator’s Binder, study  drug, subj ect m edical recor ds, informed consent documentation, 
docum entati on of  subject authori zation to use personal healt h informat ion, and review of eCRFs 
and associated source documents. It is important that the investigator and other study  personnel 
are available during the mon itoring visits and that sufficient time is devoted to the process.
14.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study  subjects. Should other unexpected circumstances a rise that will 
requi re deviat ion from protocol -specified procedures, the invest igator should consult with the 
sponsor or designee (and IRB, as required) to determine the appropriate course of action. There 
will be no exemptions (a prospectively approved de viation) from the inclusio n or exclusio n 
criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event 
of a significant deviation, the site should notify the sponsor or its designee (and IRB, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviat ion Form  shoul d be com pleted by  the si te and signed by the 
sponsor or designee for any  significant deviat ion from the protocol. 
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that thi s study  may be inspected by  regulatory  agencies, 
including those of foreign governments (eg, the Food and Drug Administration [FDA], the 
United Kingdom Medicines and Healt hcare products Regulatory  Agenc y, the Pharmaceuticals 
and Medical Devices Agency o f Japan). If the study  site is contacted for an inspect ion by a 
regul atory  body, the sponsor should be notified immediately. The invest igator guarantees access 
for quali ty assurance auditors to all study  docum ents as described in Section 14.1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 68of 86
Protocol Incorporating Amendment No. 05 19 December 2018
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GC P. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in 
Appendix B. The principles of Helsinki are addressed through the protocol and through 
appendices containing requirements for informed consent and invest igator responsibilit ies.
15.1 IRB
IRBs m ust be consti tuted according to the applicable state and federal/local requirements of each 
participat ing region. The sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB. If any member of the IRB has direct
participat ion in this study , written notificat ion regarding his or her abst inence fro m voting must 
also be obtained. Those Americas sites unwilling to provide names and tit les of all members due 
to privacy and conflict of interest concerns should instead provi de a Federal Wide Assurance 
Number or comparable number assigned by the Department of Healt h and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB for 
the protocol’s review and approval. This p rotocol , the Invest igator’s Brochure, a copy of the 
inform ed consent form , and, if applicable, subject recruitment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central  or local IRB for approval. The IRB’s written approval o f the protocol and subject 
inform ed consent m ust be obtained and submitted to the sponsor or designee before 
commencement of the study . The IRB approval must refer to the study  by exact protocol  title, 
number, and versio n date; ident ify versio ns of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will notify site once the sponsor has 
confirmed the adequacy of site regulatory  docum entati on. Unt il the site receives not ification no 
protocol  activit ies, including screening may occur.
Study  sites m ust adhere to all requirements st ipulated by their respect ive IRB. This may include 
notification to the IRB regarding protocol amendments, updates to the informed consent form, 
recrui tment m aterials intended for viewing by  subjects, l ocal safet y reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB, and submissio n of the invest igator’s final status report to IRB. All IRB approvals 
and relevant documentation for these items must be provided to the sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB and sponsor.
15.2 Subj ect Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 69of 86
Protocol Incorporating Amendment No. 05 19 December 2018
applicable law s and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted 
uses, transfers, and disclo sures of the subject’s personal and personal healt h inform ation for 
purposes of conducting the study. The informed consent form and the subject informat ion sheet 
(if applicable) further explain the nature of the study , its obj ectives, and potential risks and 
benefits, as well as the date informed consent is given . The informed consent form will detail the 
requi rements of the participant and the fact that he or she is free to withdraw at any  time wi thout 
giving a reason and without prejudice to his or her further medical care.
The invest igator is responsible for th e preparati on, content, and IRB approval o f the inform ed 
consent form and if applicable, the subject authorization form. The informed consent form, 
subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) must be 
approved b y both the IRB and the sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective 
subject. It is the respo nsibilit y of the invest igator to explain the detailed elements of the informed 
consent form, subject authorizat ion form (if applicable), and subject informat ion sheet (if 
applicable) to the subject. Informat ion shoul d be given in both oral and written form whenever 
possible and in the manner deemed appropriate by  the IRB.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity  
to: (1) inquire about details of the study  and (2) deci de whether or not to participate in the study . 
If the subject, or the subject’s legally acceptable representative, determines he or she will 
participate in the study , then the informed consent form and subject authorizat ion form (if 
applicable) must be signed and dated by  the subject, or the subject’s legally acceptable 
representative, at the time of consent and prior to the subject entering into the study . The subject 
or the subject’s legally acceptable representative should be instructed to sign using their legal 
names, not nicknames, using blue or black ballpo int ink. The invest igator must also sign and date 
the informed consent form and subject authorizat ion (if applicable) at the time of consent and 
prior to subject entering into the study; however, the sponsor may  allow a designee of the
investigator to sign to the extent permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorizat ion 
form (if applicable), and subject informat ion sheet (if applicable) sha ll be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent wa s obtained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 70of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Subjects who consented and provided a pharmacogeno mic sample for DNA analysis can 
withdraw thei r consent and request disposal of a stored sample at any  time pri or to analysis. 
Notify  sponsor of consent withdrawal.
15.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a subject identificat ion number. As 
permitted by  all applicable laws and regulations, limited subject attributes, such as sex, age, or 
date of birth, and subject init ials may be used to verify the subject and accuracy  of the subject’s 
unique identificat ion number.
To com ply with ICH Gui delines for GCP and to verify compliance with this protocol, the 
sponsor requires the investigator to permi t the m onitor or the sponsor’s designee, representatives 
from any regulatory  authori ty (eg, FDA, Medicines and Healt hcare products Regulatory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs t o review the subject’s original medical records (source data or documents), 
including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n and di scharge 
summaries for hospital admissions occurring during a subject’s study  parti cipat ion, and autopsy  
reports. Access to a subject’s original medical records requires the specific authorization o f the 
subject as part of the informed consent process (see Section 15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
15.4 Publicatio n, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The invest igator is obliged to provide the sponsor with complete test results and all data derived 
by the investigator from the study . During and after the study , only  the spo nsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the study  site agreement, any  public 
disclosure (including publicly accessible websi tes) rel ated to the protocol  or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before st art of study , as defined in Takeda Policy/Standard. Takeda 
contact informat ion, along wi th invest igator’s cit y, state (for American invest igators), country, 
and recruit ing status will be registered and available for public viewing. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 71of 86
Protocol Incorporating Amendment No. 05 19 December 2018
For some registries, Ta keda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor.
Any invest igator who objects to the sponsor providing this informat ion to callers must provide 
the sponsor with a written notice request ing that their informat ion not be listed on the registry  
site. 
15.4.3 Clinical Trial Results Dis closure
Takeda will post the results of clinical trials on ClinicalTrials.gov and/or other publicly 
accessible websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulat ions applicable to the 
site where the subject is participat ing. If a local underwriter is required, then the sponsor or 
sponsor’s designee will obtain clinical study  insurance against the risk of injury  to study  
subjects. Refer to the study  site agreement regarding the sponsor’s policy on subject 
compensat ion and treatment for injury . If the investi gator has quest ions regarding this policy, he 
or she should contact the sponsor or sponsor’s designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 72of 86
Protocol Incorporating Amendment No. 05 19 December 2018
16.0 REFERE NCES
1.Barton RG. Nutrition support in crit ical illness. Nutr Clin Pract 1994;9(4):127 -39.
2.Harrington L. Nutrit ion in crit ically ill adults: key processes and outcomes. Crit Care Nurs 
Clin North Am 2004;16(4):459 -65.
3.Slone DS. Nutr itional support of the crit ically ill and injured pat ient. Crit Care Clin 
2004;20(1):135 -57.
4.Camilleri M, Iturrino J, Bharucha AE, Burton D, Shin A, Jeong ID, et al. Performance 
characterist ics of scint igraphic measurement of gastric empt ying of so lids in healthy 
participants. Neurogastroenterol Motil 2012;24(12):1076 -e562.
5.Li Y, Ni e Y, Xi e J, Tang W, Liang P, Sha W, et al. The associat ion of serotonin transporter 
genet ic po lymorphisms and irritable bowel syndrome and its influence on tegaserod 
treatm ent in Chinese patients. Dig Dis Sci 2007;52(11):2942- 9.
6.Uppal apati  SS, Ram zan Z, Fisher RS, Parkman HP. Factors contribut ing to hospitalizat ion 
for gastroparesis exacerbat ions. Dig Dis Sci 2009;54(11):2404 -9.
7. Bharadwaj S, Meka K, Tandon P, Rathur A, Rivas JM, Vallabh H, et al. Management of 
gastroparesi s-associ ated malnutri tion. J Di g Dis 2016;17(5):285 -94.
8.Gao LB, Tian H, Wang XG, Yu XF, Guan Y, Chen ML, et al. Early enteral and parenteral 
nutritional support after hepatectomy  in pat ients wit h hepatic carcinom a: a system atic review 
and meta -analysis. Onco Targets Ther 2015;8:623 -31.
9.Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, et al. Consensus 
recommendat ions for gastri c emptying scint igraphy: a jo int report of the American 
Neurogastroenterology  and Motilit y Society  and the Soci ety of Nuclear Medicine. Am J 
Gastroenterol 2008;103(3):753 -63.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 73of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Appendix ASchedule of Study Procedures
Screening 
(a)Baseline 
(a)Treatment DaysFinal Visit or 
Early
Termination 
Visit (b)Follow -up 
Phone Call Study Day 1 2 3 4
Visit Windows (Days): -14 to -1 -14 to -1 10 -14
Informed consent X
Inclusion/exclusion criteria X X
Demographics X
Physical examination (c) X X X X X
Vital signs (d) X X X X X X
Weight, height, and BMI X
Concomitant medications X X X X X X X
Clinical laboratory tests (e) X X X X X
Fasting (finger stick) blood glucose (f) X X X X
12-lead ECG (g) X X X X X
6-hour Holter monitor X
Holter monitoring (h) X X X
PTE X X
Serum pregnancy test (hCG) (i) X X
Urine pregnancy test (j) X
Randomization X
Medication history X X
Concurrent medical conditions X X
Plasma sample for TAK -954 PK (k) X X X X
Gastroparesis Cardinal Symptom Index X
Bowel Habit Diary Card X X X X X X
Hepatitis panel X
Scintigraphy (o) X X X X (p)
Study  drug dosing X X X
AE assessment X X X X X X
Radiolabeled meals (q) X X
Charcoal administration (r) X
Footnotes are on last table page.
Property of Takeda: For mercial use only and subject to the applicable Terms of Use
CCI
CCI
CCI
TAK -954
Study No. TAK -954-2003 Page 74of 86
Protocol Incorporating Amendment No. 05 19 December 2018
(a) Screening and Baseline Visit procedures may be done on the same day.
(b) Conduct Final Visit procedures for subjects discontinued early per Section 7.5. The end of study is defined as the date of the 
last visit (Day 4) of the last subject undergoing the study unless the study is stopped earlier by sponsor.
(c) Phy sical examination will be conducted prior to dosing on Days 1, 2, and 3.
(d) Vital signs will be collected at Screening and Baseline, and on Days 1, 2, 3 and 4 up on arrival and departure from the Clinical 
Research and Trials Unit, and on Day 1, 2, and 3 prior to dosing (0 hour), 1 (end of infusion ), and 2 hours after start of infusion.
(e) Hematology, serum chemistries, and urinalysis tests. HbA1c and TSH will be a ssessed only at Screening.
(f) If the Screening and Baseline Visits are combined (same day), a fasting blood glucose (finger stick) will not be performe d if 
blood glucose is performed.
(g) 12 -lead ECG will be performed prior to each IV infusion, within 30 minutes post infusion, and at discharge on Days 1, 2, and 
3; and at the Final Visit on Day 4 or Early Termination Visit. In addition, a 12 -lead ECG will be performed when needed, if a 
subject develops symptoms or clinical signs suggestive of cardiovascular origin (eg, dizziness, lightheadedness, chest pain, chest 
heaviness, palpitations, shortness of breath, tachycardia).
(h) Holter monitor will be placed prior to dosing on Day 1 until the morning of Day 3.
(i) Women of childbearing potential. If a negative serum hCG pregnancy test was obtained on Day -1, then the serum pregnancy 
test on Day 1 can be discontinued. 
(j) Urine pregnancy test will be conducted within 48 hours prior to consuming a radiolabeled meal in women of childbearing 
potential if screening serum pregnancy test was not completed within these 48 hours. 
(k) PK timepoints will be collected as follows: 
Day 1: prior to dosing (0 hour), 1 (end of infusion), 2, and 4 hours after start of infusion.
Day 2: prior to dosing (0 hour,), 1 (end of infusion), 2, 5, 7, and 9 hours after the start of the infusion.
Day 3: prior to dosing (0 hour), 1 (end of infusion), 2, and hours after start of infusion.
Day 4: 25 hours post start of infusion on Day 3 (48 hours after the administration of the radiolabeled m eal on Day 2, same time as 
the 48- hour geometric center measurement).
(l)  
(m)  
 
.
(n)  
 
.
(o) Scintigraphy: 
Baseline at 0, 1, 2, 3, and 4 hours (240 min) post -radiolabeled meal on Days -14 to Day  -1.
Day 2 at every 0.5 hour for first 4 hours post radiolabeled meal, ie, 5 ho urs post start of infusion, then hourly until 9 hours post 
start of infusion (8 hours post radiolabeled meal) on Day 3 at 1 hour post start of infusion (24 hours post radiolabeled meal on 
Day 2), and on Day 4 at 25 hours post start of infusion on Day 3 (48 hours post radiolabeled meal on Day 2).
(p) Scintigraphy will not be performed if this is an Early Termination Visit.
(q) Radiolabeled meals administered at Baseline (between Day -14 and Day -1) and Day  2 at the end of infusion (1 hour post start 
infusion ).
(r) Radiolabeled charcoal capsule administered on Day 2 at predose (within 5 minutes of start of infusion).
Property of Takeda: For non-comm se ly and subject to the applicable Terms of Use
CCI
CCI
CCI
TAK -954
Study No. TAK -954-2003 Page 75of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Appendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), whi ch must be com pleted and 
signed before the invest igator may participat e in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of 
written approval  from relevant governing bodies/authorities.
4.Ensure that all co lleagues and emp loyees assist ing in the conduct of the study are informed 
of these obligat ions.
5.Secure prior approval of the study  and any  changes by  an appropri ate IRB that conform to 
21CFR Part 56, ICH, and local regulatory requirements.
6. Ensure that the IRB will be res ponsible for init ial review, continuing review, and approval of 
the protocol. Promptly report to the IRB all changes in research activit y and all ant icipated 
risks to subjects. Make at least yearly reports on the progress of the study  to the IRB, and 
issue a final report within 3 mo nths of study  com pletion.
7.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
8.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal healt h informat ion) that will take place in connection wit h 
the study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization fo rm from each subject or the 
subject’s legally acceptable representative.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before dis posing of any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 76of 86
Protocol Incorporating Amendment No. 05 19 December 2018
11.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 77of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Appendix CElements of the Subject Informed Consent 
In seeking informed co nsent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A stateme nt describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures of appropri ate al ternat ive procedures or courses of treatment, if any, that might 
be advantageous to the subject and their important potential risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regulatory  agencies, audi tor(s), IRB, and 
the monitor m ay inspect the records. By  signing a wri tten inform ed consent form , the subject 
or the subject’s legally acce ptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any  
compensat ion and an explanat ion as to whether any medical treatments are available if injury 
occurs and, if so, what they  cons ist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to cont act for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB and who m to contact in the event of a 
research -related inj ury to the subject.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 78of 86
Protocol Incorporating Amendment No. 05 19 December 2018
19.A statement that participat ion is vo luntary, that refusal to participate will involve no penalt y 
or loss of benefit s to whi ch the subject otherwise is entitled, and that the subject or the 
subject’s legally acceptable representative may discontinue participation at any  time without 
penalt y or l oss of benefits to which the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representative will be 
informed in a t imely manner if informat ion beco mes available that may be relevant to the 
subject’s willingness to continue participat ion in the study .
22.A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws requi re the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wri tten subject authori zation (either contained wit hin the informed consent form or 
provi ded as a separa te document) describing to the subject the contemplated and permissible 
uses and disclosures o f the subject’s personal informat ion (including personal health 
inform ation) for purposes of conducting the study . The subject authorizat ion must contain the 
following statements regarding the uses and disclo sures of the subject’s personal 
inform ation:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and sa fety reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authoriti es; and (4) IRBs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection l aws wi thin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion)may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  drug(s), studying other therapies for subjects, 
developing a better understanding of disease, and improving the effi ciency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such i nformat ion may  impact the scient ific integrity of 
the research; and
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 79of 86
Protocol Incorporating Amendment No. 05 19 December 2018
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subje cts) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) from Screening throughout the duration of the study , and for 4 to 5 days (5 half -
lives) PLUS 30days after l ast dose. Regul ar pregnancy tests will be performed throughout 
the study  for all female subjects of childbearing potential. If a subject is found to be pregnant 
during study , study  drug will be discont inued and the invest igator will o ffer the subject the 
choice to receive unblinded treatment infor mation.
26.Male subjects must use highly effect ive contraceptio n (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study , and for 4 to 5 days 
(5half-lives) PLUS 30 days after last dose. If the partner or wife of the subject is found to be 
pregnant during the study , the invest igator will offer the subject the cho ice to receive 
unblinded treatment informat ion.
27.A statement that clinical trial informat ion from this trial will be publicly disclo sed in a 
publicl y accessible website, such as ClinicalTrials.gov.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 80of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Appendix DInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and oth er personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verif ication of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of reg ulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to other medications used in other clinical studies that may 
contain the same chemical compound present in the study  drug.
Inspect ions and invest igations by regulatory  auth orities relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in investigator’s 
own country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 81of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Appendix EHepatic Function Categories Based on Child -Pugh Score
Classificat ion of clinical severit y:
Mild (Class A): total score 5 -6 points.
Moderate (Class B): total score 7 -9 points.
Severe (Class C): total score 10- 15 points.
Assessment Parameters Points Scored for Observed Findings
1 point 2 points 3 points
Encephalopathy grade (a) none 1 or 2 3 or 4
Ascites absence slight moderate
Serum bilirubin, mg/dL <2 2 to 3 >3
Serum albumin, g/dL >3.5 2.8 to 3.5 <2.8
INR <1.7 1.7-2.3 >2.3
Source: 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
(a) Grade 0: normal consciousness, personality, neurological examination, electroencephalogram.
Grade 1: restless, sleep disturbed, irritable/agitated, tre mor, impaired handwriting, 5 cycles per second (cps) waves.
Grade 2: lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves.
Grade 3: somnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves.
Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 -3 cps delta activity.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 82of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Appendix FDetailed Descriptions of Amendments to Text
The primary  secti ons of the protocol affected by  the changes in Amendment 05 are in dicated. 
The corresponding text has been revised throughout the protocol. 
Change 1:Revised number of subjects based on the findings of the interim analysis.
The primary  change occurs in Section 2.0STU DY SUMMARY .
Initial 
wording:Number of Subjects:
48 (12 per group)
Amended 
or new 
wording:Number of Subjects:
48Approximately 36 to 41 subjects (maximum of 12 per group) .
Rationale for Change:
One dosing arm  was dropped based on conclusio ns obtained from the unblinded execut ive 
committee who performed the interim analysis.
Secti on 2.0STU DY SUMMARY also contains this change. 
Change 2:Decreased the number of active treatment arms.
The primary  change occurs in Section 8.1.3 Dose and Regimen .
Initial 
wording:The subjects will be randomized to 1 of 4 treatment arms : TAK -954 0.1, 0.3, or 
1mg; or pl acebo and will receive TAK -954 or pl acebo as a 60 -minutes infusio n IV 
once a day  for 3 day s starting on Day  1. 
Amended 
or new 
wording:The subjects will be randomized to 1 of 4 treatment arms :TAK -954 0.1, 0.3, or 
1mg; or pl acebo and will receive TAK -954 or pl acebo as a 60 -minutes infusio n IV 
once a day  for 3 day s starting on Day  1. The number of active treatment arms 
decreased based upon the prespecified interim analysis. Tomaintain the 
blind ing of the study team, the specific treatment arm is not identified. This 
change was not necessitated by safety findings.
Rationale for Change:
Based on conclusio ns obtained fro m the unblinded execut ive co mmit tee who perform ed the 
interim analysis.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 83of 86
Protocol Incorporating Amendment No. 05 19 December 2018
The following sect ions also contain this change:
Secti on 2.0STU DY SUMMARY .
Secti on 6.1Study  Design .
Secti on 9.1.16 Documentation of Rando mizat ion.
13.2 Interim Analysis and Criteria for Early Terminat ion.
Table 13.a.
Change 3:Revised the type of vital sign procedures collected and clarified the timing in relation 
to pharmacokinetic (PK) blood draws.
The primary  change occurs in Section 9.1.5 Vital Sign Procedure .
Initial 
wording:Vital signs will  include body  temperature (oral  measurement), respiratory  rate, 
sitting/supine blood pressure (systolic and diastolic, resting more than 5 minutes), 
and pulse (beats per minute).
When vital signs are scheduled at the same t ime as blood draws, the blood draw will 
take priorit y and vital signs will be o btained within 0.5 hour before or after the 
scheduled blood draw.
Amended 
or new 
wording:Vital signs will  include body  temperature (oral  measurement), respiratory  rate,
sitting/supine blood pressure (systolic and diastolic, resting more than 5 minutes), 
and pulse (beats per minute).
When vital signs are scheduled at the same t ime as PKblood draws, the PKblood 
draw will take priority  and vi tal signs will be obtained wit hin 0.5 hour before or after 
the scheduled blood draw.
Rationale for Change:
Decrease the number of procedures needed and clarify the timing in relation to PK blood draws.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 84of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Change 4: Eliminat ion of optional PK samples.
The primary  change occurs in Section 9.1.14.1 Collection of Plasma for PK Sampli ng.
Initial 
wording:The subjects will have PK samples co llected as follows:
Days 1: prior to dosing (0 hour), and at 0.5 (optional), 1 (end of infusio n), 1.5 
(opti onal), 2, and 4 hours after start of infusio n. 
Day 2: pri or to dosing (0 hour), 0.5 (optional), 1 (end of infusion), 1.5 (optional), 2, 
5, 7, and 9 hours after the start of the infusio n. 
Day 3:prior to dosing (0 hour), 0.5 (optional), 1 (end of infusion), 1.5 (optional), 2, 
and 4 (opti onal) hours aft er start of infusio n.
Amended 
or new 
wording:The subjects will have PK samples co llected as follows:
Days 1: prior to dosing (0 hour), and at 0.5 (optional), 1 (end of infusio n), 1.5 
(opti onal),2, and 4 hours after start of infusio n. 
Day 2: pri or to do sing (0 hour), 0.5 (optional), 1 (end of infusion), 1.5 (opti onal),2, 
5, 7, and 9 hours after the start of the infusio n. 
Day 3:prior to dosing (0 hour), 0.5 (optional), 1 (end of infusion), 1.5 (opti onal), 
and 2, and4(optional)hours after start of infusio n.
Rationale for Change:
To decrease the amount of blood needed from subjects.
The fo llowing sect ions also contain this change:
Secti on 2.0STU DY SUMMARY also contains this change.
Figure 6.aSchemat ic of Study  Design .
Table 9.b. Primary Specimen Co llections.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 85of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Change 5Revised the timing of vital sign measurements.
The primary  change occurs in Appendix ASchedule of Study  Procedures .
Initial 
wording:(d) Vi tal signs will be collected upon arrival and departure from the Clinical 
Research and Trials Unit, and at the time of the PK samples.
Amended 
or new 
wording:(d) Vi tal signs will be collected at Screening and Baseline, and on Days 1, 2, 3, 
and 4 upon arrival and departure from the Clinical Research and Trials Unit, and at 
the time and on Days 1, 2, and 3 prior to dosing (0 hour), 1 (end of the PK sample
infusion), and 2 hours after start of inf usion .
Rationale for Change:
Correcti on of  vital sign measurement timing.
Change 6:Eliminated instruction of the timing of PK sam pling and electrocardi ogram
procedures.
The primary  change occurs in Section 9.1.14.1 Collection of Plasma for PK Sampli ng.
Deleted 
text:When a PK sample co incides with a n ECG or vital signs measurement, the ECG will 
take priorit y over the vital signs measurement.
Rationale for Change :
As the drug is administered via IV infusio n, it is important to have the PK sample obtained as 
soon as possible at the end of infusio n in order to cal culate the C max. Wai ting for an ECG 
measurement will significant ly increase the variabilit y across subjects. There is no safety  issue 
for doing i t either way .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study No. TAK -954-2003 Page 86of 86
Protocol Incorporating Amendment No. 05 19 December 2018
Change 7:Revised informat ion related to interim analysis.
The primary  change occurs in Secti on 13.2 Interim Analysis and Criteria for Early Termination .
Initial 
wording:An interim analysis will be conducted when approximately  half of the subjects have 
completed the study . Efficacy  and safety  data will be reviewed to determine if the 
study  shoul d be m odified based on the interim analysis results. If needed, the 
changes will be related to dose select ion, sample size modification, or study  
termination. 
An execut ive co mmit tee wi thin Takeda co mposed of a senior clinician, a senior 
statist ician,a senior clinical pharmaco logist, and a senior pharmacovigilance 
scientist not involved in the study  will review the interim analysis results and make 
recommendat ions for changes to the study , if appropri ate. All members o f the study  
team  and the invest igative team will remain blinded to treatment arm assignment and 
treatm ent arm  resul ts unt il the complet ion of the study .
Amended 
or new 
wording:An interim analysis will bewas conducted when approximately  half of the subjects 
have co mpleted the study . Efficacy  and safet y data will be was reviewed to 
determine if the study  shoul d be m odified based on the interim analysis results. If 
needed, the changes will be related to dose sel ection, sample size modificat ion, or 
study  terminat ion. 
An execut ive co mmit tee wi thin Takeda co mposed of a senior clinician, a senior 
statist ician, a senior clinical pharmaco logist, and a senior pharmacovigilance 
scientist not involved in the study  willhave review reviewed the interim analysis 
resul ts and make made recommendat ions for changes to the study , if appropri ate. 
All members of the study  team  and the invest igative team will remain blinded to 
treatm ent arm  assignment and treatm ent arm  resul ts unt il the com pletion of the 
study .
Based upon the results of the preplanned interim analysis, 1 of the TAK -954 
doses was dropped. The specific dose dropped is not specified in order to 
maintain the blind of the study team. The sample size for the remaining 
treatment arms will not change.
Rationale for Change :
Based on conclusio ns obtained fro m the unblinded execut ive co mmit tee who perform ed the 
interim analysis.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

    
 
  
 
  
 
ELECTRONIC SIGNATURES  
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
   
  
   
  
   
  
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 
090101d6809fbaa4Amendment 05 to A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of
TAK-954 on Gastrointestinal and Colonic Transit in Patients with Diabetic or Idiopathic Gastroparesis
Clinical Science Approval 20-Dec-2018 14:59 UTC
Statistical Approval 20-Dec-2018 15:28 UTC
Pharmacovigilance Approval 20-Dec-2018 15:30 UTC
Clinical Pharmacology Approval 20-Dec-2018 18:55 UTC
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
PPD